{"entity":"eli-lilly","name":"Eli Lilly and Company","kind":null,"summary":"Eli Lilly and Company's timeline holds 509 claims from 1994 to 2026: 499 money & deals, 10 other. 7 are undated. The latest took effect on October 26, 2026.","counts":{"total":509,"by_kind":{"people":0,"money":499,"products":0,"models":0,"other":10}},"events":[{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company sic industry: Pharmaceutical Preparations (2834)\", undated. Claim clm_2509C2A3A267, https://asof.is/claim/clm_2509C2A3A267, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478.","url":"https://asof.is/claim/clm_2509C2A3A267","accessed":"2026-11-08"},"kind":"other","predicate":"sic_industry","value":"Pharmaceutical Preparations (2834)","status":"valid","assertable":true,"id":"clm_2509C2A3A267","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company fiscal year end: 12-31\", undated. Claim clm_4809DE70CF2A, https://asof.is/claim/clm_4809DE70CF2A, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478.","url":"https://asof.is/claim/clm_4809DE70CF2A","accessed":"2026-11-08"},"kind":"other","predicate":"fiscal_year_end","value":"12-31","status":"valid","assertable":true,"id":"clm_4809DE70CF2A","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company headquarters: Indianapolis\", undated. Claim clm_8346D7F2C725, https://asof.is/claim/clm_8346D7F2C725, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478.","url":"https://asof.is/claim/clm_8346D7F2C725","accessed":"2026-11-08"},"kind":"other","predicate":"headquarters","value":"Indianapolis","status":"valid","assertable":true,"id":"clm_8346D7F2C725","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cik: 0000059478\", undated. Claim clm_91F284A9D7C8, https://asof.is/claim/clm_91F284A9D7C8, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478.","url":"https://asof.is/claim/clm_91F284A9D7C8","accessed":"2026-11-08"},"kind":"other","predicate":"cik","value":"0000059478","status":"valid","assertable":true,"id":"clm_91F284A9D7C8","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company state of incorporation: IN\", undated. Claim clm_A5EA16045303, https://asof.is/claim/clm_A5EA16045303, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478.","url":"https://asof.is/claim/clm_A5EA16045303","accessed":"2026-11-08"},"kind":"other","predicate":"state_of_incorporation","value":"IN","status":"valid","assertable":true,"id":"clm_A5EA16045303","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company listed on: NYSE\", undated. Claim clm_B1897509C990, https://asof.is/claim/clm_B1897509C990, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478.","url":"https://asof.is/claim/clm_B1897509C990","accessed":"2026-11-08"},"kind":"other","predicate":"listed_on","value":"NYSE","status":"valid","assertable":true,"id":"clm_B1897509C990","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":null,"undated":true,"until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company ticker: LLY\", undated. Claim clm_E590A7180C31, https://asof.is/claim/clm_E590A7180C31, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478.","url":"https://asof.is/claim/clm_E590A7180C31","accessed":"2026-11-08"},"kind":"other","predicate":"ticker","value":"LLY","status":"valid","assertable":true,"id":"clm_E590A7180C31","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":"1994-07-27","until":"1994-10-14","published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company registrant name: LILLY ELI & CO ET AL\", as of 1994-07-27 (until 1994-10-14). Claim clm_48D2AB64E8F2, https://asof.is/claim/clm_48D2AB64E8F2, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478.","url":"https://asof.is/claim/clm_48D2AB64E8F2","accessed":"2026-11-08"},"kind":"other","predicate":"registrant_name","value":"LILLY ELI & CO ET AL","status":"superseded","assertable":true,"id":"clm_48D2AB64E8F2","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":"1994-10-26","until":"2019-10-25","published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company registrant name: LILLY ELI & CO\", as of 1994-10-26 (until 2019-10-25). Claim clm_C9CDC9028127, https://asof.is/claim/clm_C9CDC9028127, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478.","url":"https://asof.is/claim/clm_C9CDC9028127","accessed":"2026-11-08"},"kind":"other","predicate":"registrant_name","value":"LILLY ELI & CO","status":"superseded","assertable":true,"id":"clm_C9CDC9028127","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":"2006-12-31","until":"2007-12-31","published":"2010-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,109,300,000 United States dollar\", as of 2006-12-31 (until 2007-12-31). Claim clm_AD699CB69989, https://asof.is/claim/clm_AD699CB69989, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310014958/0000950123-10-014958-index.htm.","url":"https://asof.is/claim/clm_AD699CB69989","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,109,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AD699CB69989","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2009, filed 2010-02-22"}},{"date":"2007-12-31","until":"2008-06-30","published":"2010-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,220,500,000 United States dollar\", as of 2007-12-31 (until 2008-06-30). Claim clm_0D3E370EA1BC, https://asof.is/claim/clm_0D3E370EA1BC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310014958/0000950123-10-014958-index.htm.","url":"https://asof.is/claim/clm_0D3E370EA1BC","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,220,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0D3E370EA1BC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2009, filed 2010-02-22"}},{"date":"2007-12-31","until":"2008-12-31","published":"2010-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company revenue: 18,633,500,000 United States dollar\", as of 2007-12-31 (until 2008-12-31). Claim clm_6C192C099D33, https://asof.is/claim/clm_6C192C099D33, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310014958/0000950123-10-014958-index.htm.","url":"https://asof.is/claim/clm_6C192C099D33","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"18,633,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6C192C099D33","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2009, filed 2010-02-22"}},{"date":"2007-12-31","until":"2008-12-31","published":"2010-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company research and development: 3,486,700,000 United States dollar\", as of 2007-12-31 (until 2008-12-31). Claim clm_A38CF4ED791C, https://asof.is/claim/clm_A38CF4ED791C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310014958/0000950123-10-014958-index.htm.","url":"https://asof.is/claim/clm_A38CF4ED791C","accessed":"2026-11-08"},"kind":"money","predicate":"research_and_development","value":"3,486,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A38CF4ED791C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2009, filed 2010-02-22"}},{"date":"2007-12-31","until":"2008-12-31","published":"2010-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company net income: 2,953,000,000 United States dollar\", as of 2007-12-31 (until 2008-12-31). Claim clm_F48D85F877C4, https://asof.is/claim/clm_F48D85F877C4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310014958/0000950123-10-014958-index.htm.","url":"https://asof.is/claim/clm_F48D85F877C4","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"2,953,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F48D85F877C4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2009, filed 2010-02-22"}},{"date":"2008-06-30","until":"2008-09-30","published":"2009-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,150,400,000 United States dollar\", as of 2008-06-30 (until 2008-09-30). Claim clm_1102EFDDC838, https://asof.is/claim/clm_1102EFDDC838, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012309028099/0000950123-09-028099-index.htm.","url":"https://asof.is/claim/clm_1102EFDDC838","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,150,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1102EFDDC838","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2009, filed 2009-07-31"}},{"date":"2008-06-30","until":"2008-09-30","published":"2009-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 958,800,000 United States dollar\", as of 2008-06-30 (until 2008-09-30). Claim clm_23B6FA8228EF, https://asof.is/claim/clm_23B6FA8228EF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012309028099/0000950123-09-028099-index.htm.","url":"https://asof.is/claim/clm_23B6FA8228EF","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"958,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_23B6FA8228EF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2009, filed 2009-07-31"}},{"date":"2008-06-30","until":"2008-09-30","published":"2009-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 2,868,300,000 United States dollar\", as of 2008-06-30 (until 2008-09-30). Claim clm_BCE9C7519379, https://asof.is/claim/clm_BCE9C7519379, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012309028099/0000950123-09-028099-index.htm.","url":"https://asof.is/claim/clm_BCE9C7519379","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,868,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BCE9C7519379","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2009, filed 2009-07-31"}},{"date":"2008-06-30","until":"2008-09-30","published":"2009-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 951,500,000 United States dollar\", as of 2008-06-30 (until 2008-09-30). Claim clm_DBACEC763B3F, https://asof.is/claim/clm_DBACEC763B3F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012309028099/0000950123-09-028099-index.htm.","url":"https://asof.is/claim/clm_DBACEC763B3F","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"951,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DBACEC763B3F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2009, filed 2009-07-31"}},{"date":"2008-09-30","until":"2008-12-31","published":"2009-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 4,353,600,000 United States dollar\", as of 2008-09-30 (until 2008-12-31). Claim clm_1D6956B778D3, https://asof.is/claim/clm_1D6956B778D3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012309055409/0000950123-09-055409-index.htm.","url":"https://asof.is/claim/clm_1D6956B778D3","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"4,353,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1D6956B778D3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2009, filed 2009-10-30"}},{"date":"2008-09-30","until":"2009-03-31","published":"2009-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: -465,600,000 United States dollar\", as of 2008-09-30 (until 2009-03-31). Claim clm_2C0E273C772B, https://asof.is/claim/clm_2C0E273C772B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012309055409/0000950123-09-055409-index.htm.","url":"https://asof.is/claim/clm_2C0E273C772B","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"-465,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2C0E273C772B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2009, filed 2009-10-30"}},{"date":"2008-09-30","until":"2009-03-31","published":"2009-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 953,000,000 United States dollar\", as of 2008-09-30 (until 2009-03-31). Claim clm_5846C31AE43C, https://asof.is/claim/clm_5846C31AE43C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012309055409/0000950123-09-055409-index.htm.","url":"https://asof.is/claim/clm_5846C31AE43C","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"953,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5846C31AE43C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2009, filed 2009-10-30"}},{"date":"2008-09-30","until":"2009-03-31","published":"2009-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,209,500,000 United States dollar\", as of 2008-09-30 (until 2009-03-31). Claim clm_FC4E2F880E31, https://asof.is/claim/clm_FC4E2F880E31, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012309055409/0000950123-09-055409-index.htm.","url":"https://asof.is/claim/clm_FC4E2F880E31","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,209,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FC4E2F880E31","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2009, filed 2009-10-30"}},{"date":"2008-12-31","until":"2009-03-31","published":"2010-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 5,496,700,000 United States dollar\", as of 2008-12-31 (until 2009-03-31). Claim clm_483FA20E20C6, https://asof.is/claim/clm_483FA20E20C6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310014958/0000950123-10-014958-index.htm.","url":"https://asof.is/claim/clm_483FA20E20C6","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"5,496,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_483FA20E20C6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2009, filed 2010-02-22"}},{"date":"2008-12-31","until":"2009-06-30","published":"2010-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 29,212,600,000 United States dollar\", as of 2008-12-31 (until 2009-06-30). Claim clm_9CDC07565E1C, https://asof.is/claim/clm_9CDC07565E1C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310014958/0000950123-10-014958-index.htm.","url":"https://asof.is/claim/clm_9CDC07565E1C","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"29,212,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9CDC07565E1C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2009, filed 2010-02-22"}},{"date":"2008-12-31","until":"2009-12-31","published":"2010-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company net income: -2,071,900,000 United States dollar\", as of 2008-12-31 (until 2009-12-31). Claim clm_A9151DC389AD, https://asof.is/claim/clm_A9151DC389AD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310014958/0000950123-10-014958-index.htm.","url":"https://asof.is/claim/clm_A9151DC389AD","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"-2,071,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A9151DC389AD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2009, filed 2010-02-22"}},{"date":"2008-12-31","until":"2009-12-31","published":"2010-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company research and development: 3,840,900,000 United States dollar\", as of 2008-12-31 (until 2009-12-31). Claim clm_AFD07F967D55, https://asof.is/claim/clm_AFD07F967D55, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310014958/0000950123-10-014958-index.htm.","url":"https://asof.is/claim/clm_AFD07F967D55","accessed":"2026-11-08"},"kind":"money","predicate":"research_and_development","value":"3,840,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AFD07F967D55","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2009, filed 2010-02-22"}},{"date":"2008-12-31","until":"2009-06-30","published":"2010-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 6,737,700,000 United States dollar\", as of 2008-12-31 (until 2009-06-30). Claim clm_EF820B53A635, https://asof.is/claim/clm_EF820B53A635, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310014958/0000950123-10-014958-index.htm.","url":"https://asof.is/claim/clm_EF820B53A635","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"6,737,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EF820B53A635","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-K FY2009, filed 2010-02-22"}},{"date":"2008-12-31","until":"2009-12-31","published":"2010-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company revenue: 20,371,900,000 United States dollar\", as of 2008-12-31 (until 2009-12-31). Claim clm_F31DE382AAED, https://asof.is/claim/clm_F31DE382AAED, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310014958/0000950123-10-014958-index.htm.","url":"https://asof.is/claim/clm_F31DE382AAED","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"20,371,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F31DE382AAED","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2009, filed 2010-02-22"}},{"date":"2009-03-31","until":"2009-06-30","published":"2010-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,313,100,000 United States dollar\", as of 2009-03-31 (until 2009-06-30). Claim clm_11A5247EA3F6, https://asof.is/claim/clm_11A5247EA3F6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310041274/0000950123-10-041274-index.htm.","url":"https://asof.is/claim/clm_11A5247EA3F6","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,313,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_11A5247EA3F6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2010, filed 2010-04-30"}},{"date":"2009-03-31","until":"2009-06-30","published":"2010-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,047,000,000 United States dollar\", as of 2009-03-31 (until 2009-06-30). Claim clm_59E4AE9C36CB, https://asof.is/claim/clm_59E4AE9C36CB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310041274/0000950123-10-041274-index.htm.","url":"https://asof.is/claim/clm_59E4AE9C36CB","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,047,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_59E4AE9C36CB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2010, filed 2010-04-30"}},{"date":"2009-03-31","until":"2009-06-30","published":"2010-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,313,100,000 United States dollar\", as of 2009-03-31 (until 2009-06-30). Claim clm_B84BC0F12DF0, https://asof.is/claim/clm_B84BC0F12DF0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310041274/0000950123-10-041274-index.htm.","url":"https://asof.is/claim/clm_B84BC0F12DF0","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,313,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B84BC0F12DF0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2010, filed 2010-04-30"}},{"date":"2009-03-31","until":"2009-06-30","published":"2010-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 947,300,000 United States dollar\", as of 2009-03-31 (until 2009-06-30). Claim clm_F12D855DD720, https://asof.is/claim/clm_F12D855DD720, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310041274/0000950123-10-041274-index.htm.","url":"https://asof.is/claim/clm_F12D855DD720","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"947,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F12D855DD720","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2010, filed 2010-04-30"}},{"date":"2009-06-30","until":"2009-09-30","published":"2009-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,040,400,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_10AEF85D5BA1, https://asof.is/claim/clm_10AEF85D5BA1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012309028099/0000950123-09-028099-index.htm.","url":"https://asof.is/claim/clm_10AEF85D5BA1","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,040,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_10AEF85D5BA1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2009, filed 2009-07-31"}},{"date":"2009-06-30","until":"2009-09-30","published":"2009-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 26,931,500,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_70F0A12AA6B3, https://asof.is/claim/clm_70F0A12AA6B3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012309028099/0000950123-09-028099-index.htm.","url":"https://asof.is/claim/clm_70F0A12AA6B3","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"26,931,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_70F0A12AA6B3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2009, filed 2009-07-31"}},{"date":"2009-06-30","until":"2009-09-30","published":"2009-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,292,800,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_7DCE73A04E98, https://asof.is/claim/clm_7DCE73A04E98, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012309028099/0000950123-09-028099-index.htm.","url":"https://asof.is/claim/clm_7DCE73A04E98","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,292,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7DCE73A04E98","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2009, filed 2009-07-31"}},{"date":"2009-06-30","until":"2009-09-30","published":"2009-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 8,560,000,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_C10711390F1D, https://asof.is/claim/clm_C10711390F1D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012309028099/0000950123-09-028099-index.htm.","url":"https://asof.is/claim/clm_C10711390F1D","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"8,560,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C10711390F1D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-Q Q2 FY2009, filed 2009-07-31"}},{"date":"2009-06-30","until":"2009-09-30","published":"2009-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,322,300,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_E382BCF8A181, https://asof.is/claim/clm_E382BCF8A181, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012309028099/0000950123-09-028099-index.htm.","url":"https://asof.is/claim/clm_E382BCF8A181","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,322,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E382BCF8A181","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2009, filed 2009-07-31"}},{"date":"2009-06-30","until":"2009-09-30","published":"2009-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,158,500,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_F59E65369CFD, https://asof.is/claim/clm_F59E65369CFD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012309028099/0000950123-09-028099-index.htm.","url":"https://asof.is/claim/clm_F59E65369CFD","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,158,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F59E65369CFD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2009, filed 2009-07-31"}},{"date":"2009-07-20","until":"2009-10-20","published":"2009-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,149,021,510 shares\", as of 2009-07-20 (until 2009-10-20). Claim clm_78D371C35EC1, https://asof.is/claim/clm_78D371C35EC1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012309028099/0000950123-09-028099-index.htm.","url":"https://asof.is/claim/clm_78D371C35EC1","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,149,021,510 shares","status":"superseded","assertable":true,"id":"clm_78D371C35EC1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2009, filed 2009-07-31"}},{"date":"2009-09-30","until":"2010-03-31","published":"2009-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,122,100,000 United States dollar\", as of 2009-09-30 (until 2010-03-31). Claim clm_15E0E04D9E8A, https://asof.is/claim/clm_15E0E04D9E8A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012309055409/0000950123-09-055409-index.htm.","url":"https://asof.is/claim/clm_15E0E04D9E8A","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,122,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_15E0E04D9E8A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2009, filed 2009-10-30"}},{"date":"2009-09-30","until":"2009-12-31","published":"2009-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,848,200,000 United States dollar\", as of 2009-09-30 (until 2009-12-31). Claim clm_190352900D17, https://asof.is/claim/clm_190352900D17, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012309055409/0000950123-09-055409-index.htm.","url":"https://asof.is/claim/clm_190352900D17","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,848,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_190352900D17","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2009, filed 2009-10-30"}},{"date":"2009-09-30","until":"2010-03-31","published":"2009-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 941,800,000 United States dollar\", as of 2009-09-30 (until 2010-03-31). Claim clm_36724E08FB42, https://asof.is/claim/clm_36724E08FB42, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012309055409/0000950123-09-055409-index.htm.","url":"https://asof.is/claim/clm_36724E08FB42","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"941,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_36724E08FB42","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2009, filed 2009-10-30"}},{"date":"2009-09-30","until":"2009-12-31","published":"2009-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 27,127,900,000 United States dollar\", as of 2009-09-30 (until 2009-12-31). Claim clm_5A19DBD93FC2, https://asof.is/claim/clm_5A19DBD93FC2, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012309055409/0000950123-09-055409-index.htm.","url":"https://asof.is/claim/clm_5A19DBD93FC2","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"27,127,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5A19DBD93FC2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2009, filed 2009-10-30"}},{"date":"2009-09-30","until":"2009-12-31","published":"2009-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 9,905,000,000 United States dollar\", as of 2009-09-30 (until 2009-12-31). Claim clm_76B236DB1A35, https://asof.is/claim/clm_76B236DB1A35, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012309055409/0000950123-09-055409-index.htm.","url":"https://asof.is/claim/clm_76B236DB1A35","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"9,905,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_76B236DB1A35","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-Q Q3 FY2009, filed 2009-10-30"}},{"date":"2009-09-30","until":"2010-03-31","published":"2009-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,562,000,000 United States dollar\", as of 2009-09-30 (until 2010-03-31). Claim clm_DC9E250C63CB, https://asof.is/claim/clm_DC9E250C63CB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012309055409/0000950123-09-055409-index.htm.","url":"https://asof.is/claim/clm_DC9E250C63CB","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,562,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DC9E250C63CB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2009, filed 2009-10-30"}},{"date":"2009-10-20","until":"2010-02-12","published":"2009-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,149,022,405 shares\", as of 2009-10-20 (until 2010-02-12). Claim clm_2ED8FC221F63, https://asof.is/claim/clm_2ED8FC221F63, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012309055409/0000950123-09-055409-index.htm.","url":"https://asof.is/claim/clm_2ED8FC221F63","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,149,022,405 shares","status":"superseded","assertable":true,"id":"clm_2ED8FC221F63","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2009, filed 2009-10-30"}},{"date":"2009-12-31","until":"2010-12-31","published":"2010-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company research and development: 4,326,500,000 United States dollar\", as of 2009-12-31 (until 2010-12-31). Claim clm_21AC62604A75, https://asof.is/claim/clm_21AC62604A75, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310014958/0000950123-10-014958-index.htm.","url":"https://asof.is/claim/clm_21AC62604A75","accessed":"2026-11-08"},"kind":"money","predicate":"research_and_development","value":"4,326,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_21AC62604A75","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2009, filed 2010-02-22"}},{"date":"2009-12-31","until":"2010-03-31","published":"2010-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 9,525,300,000 United States dollar\", as of 2009-12-31 (until 2010-03-31). Claim clm_2DB2351A5E3F, https://asof.is/claim/clm_2DB2351A5E3F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310014958/0000950123-10-014958-index.htm.","url":"https://asof.is/claim/clm_2DB2351A5E3F","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"9,525,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2DB2351A5E3F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-K FY2009, filed 2010-02-22"}},{"date":"2009-12-31","until":"2010-03-31","published":"2010-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 27,460,900,000 United States dollar\", as of 2009-12-31 (until 2010-03-31). Claim clm_2EE0E53C5274, https://asof.is/claim/clm_2EE0E53C5274, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310014958/0000950123-10-014958-index.htm.","url":"https://asof.is/claim/clm_2EE0E53C5274","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"27,460,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2EE0E53C5274","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2009, filed 2010-02-22"}},{"date":"2009-12-31","until":"2010-12-31","published":"2010-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company net income: 4,328,800,000 United States dollar\", as of 2009-12-31 (until 2010-12-31). Claim clm_5EE235488841, https://asof.is/claim/clm_5EE235488841, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310014958/0000950123-10-014958-index.htm.","url":"https://asof.is/claim/clm_5EE235488841","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"4,328,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5EE235488841","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2009, filed 2010-02-22"}},{"date":"2009-12-31","until":"2010-12-31","published":"2010-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company revenue: 21,836,000,000 United States dollar\", as of 2009-12-31 (until 2010-12-31). Claim clm_75C93A8D0879, https://asof.is/claim/clm_75C93A8D0879, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310014958/0000950123-10-014958-index.htm.","url":"https://asof.is/claim/clm_75C93A8D0879","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"21,836,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_75C93A8D0879","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2009, filed 2010-02-22"}},{"date":"2009-12-31","until":"2010-03-31","published":"2010-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 4,462,900,000 United States dollar\", as of 2009-12-31 (until 2010-03-31). Claim clm_D62236685DDC, https://asof.is/claim/clm_D62236685DDC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310014958/0000950123-10-014958-index.htm.","url":"https://asof.is/claim/clm_D62236685DDC","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"4,462,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D62236685DDC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2009, filed 2010-02-22"}},{"date":"2010-02-12","until":"2010-04-20","published":"2010-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,153,145,432 shares\", as of 2010-02-12 (until 2010-04-20). Claim clm_E06082706B29, https://asof.is/claim/clm_E06082706B29, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310014958/0000950123-10-014958-index.htm.","url":"https://asof.is/claim/clm_E06082706B29","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,153,145,432 shares","status":"superseded","assertable":true,"id":"clm_E06082706B29","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2009, filed 2010-02-22"}},{"date":"2010-03-31","until":"2010-06-30","published":"2010-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,039,100,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_0520A3172746, https://asof.is/claim/clm_0520A3172746, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310041274/0000950123-10-041274-index.htm.","url":"https://asof.is/claim/clm_0520A3172746","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,039,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0520A3172746","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2010, filed 2010-04-30"}},{"date":"2010-03-31","until":"2010-06-30","published":"2010-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 4,725,200,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_23A59C397ADF, https://asof.is/claim/clm_23A59C397ADF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310041274/0000950123-10-041274-index.htm.","url":"https://asof.is/claim/clm_23A59C397ADF","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"4,725,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_23A59C397ADF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2010, filed 2010-04-30"}},{"date":"2010-03-31","until":"2010-06-30","published":"2010-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 27,197,800,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_2AC520521790, https://asof.is/claim/clm_2AC520521790, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310041274/0000950123-10-041274-index.htm.","url":"https://asof.is/claim/clm_2AC520521790","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"27,197,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2AC520521790","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2010, filed 2010-04-30"}},{"date":"2010-03-31","until":"2010-06-30","published":"2010-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,248,100,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_517DCA2A54BA, https://asof.is/claim/clm_517DCA2A54BA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310041274/0000950123-10-041274-index.htm.","url":"https://asof.is/claim/clm_517DCA2A54BA","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,248,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_517DCA2A54BA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2010, filed 2010-04-30"}},{"date":"2010-03-31","until":"2010-06-30","published":"2010-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,485,500,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_8F20DCC9E865, https://asof.is/claim/clm_8F20DCC9E865, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310041274/0000950123-10-041274-index.htm.","url":"https://asof.is/claim/clm_8F20DCC9E865","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,485,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8F20DCC9E865","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2010, filed 2010-04-30"}},{"date":"2010-03-31","until":"2010-06-30","published":"2010-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 10,462,300,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_94E485E9D35E, https://asof.is/claim/clm_94E485E9D35E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310041274/0000950123-10-041274-index.htm.","url":"https://asof.is/claim/clm_94E485E9D35E","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"10,462,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_94E485E9D35E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-Q Q1 FY2010, filed 2010-04-30"}},{"date":"2010-04-20","until":"2010-07-20","published":"2010-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,153,140,541 shares\", as of 2010-04-20 (until 2010-07-20). Claim clm_D07BF22B0B77, https://asof.is/claim/clm_D07BF22B0B77, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310041274/0000950123-10-041274-index.htm.","url":"https://asof.is/claim/clm_D07BF22B0B77","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,153,140,541 shares","status":"superseded","assertable":true,"id":"clm_D07BF22B0B77","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2010, filed 2010-04-30"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,748,700,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_A35F7484BB60, https://asof.is/claim/clm_A35F7484BB60, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310070596/0000950123-10-070596-index.htm.","url":"https://asof.is/claim/clm_A35F7484BB60","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,748,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A35F7484BB60","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q/A Q2 FY2010, filed 2010-08-02"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,348,900,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_B4284D186BEA, https://asof.is/claim/clm_B4284D186BEA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310070596/0000950123-10-070596-index.htm.","url":"https://asof.is/claim/clm_B4284D186BEA","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,348,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B4284D186BEA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q/A Q2 FY2010, filed 2010-08-02"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,187,200,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_CA57488E244D, https://asof.is/claim/clm_CA57488E244D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310070596/0000950123-10-070596-index.htm.","url":"https://asof.is/claim/clm_CA57488E244D","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,187,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CA57488E244D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q/A Q2 FY2010, filed 2010-08-02"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 5,163,500,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_CD4A9AF23672, https://asof.is/claim/clm_CD4A9AF23672, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310070596/0000950123-10-070596-index.htm.","url":"https://asof.is/claim/clm_CD4A9AF23672","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"5,163,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CD4A9AF23672","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q/A Q2 FY2010, filed 2010-08-02"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 27,723,100,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_E442336E02C1, https://asof.is/claim/clm_E442336E02C1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310070596/0000950123-10-070596-index.htm.","url":"https://asof.is/claim/clm_E442336E02C1","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"27,723,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E442336E02C1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q/A Q2 FY2010, filed 2010-08-02"}},{"date":"2010-06-30","until":"2010-09-30","published":"2010-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 10,235,300,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_FBAE96E2C630, https://asof.is/claim/clm_FBAE96E2C630, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310070596/0000950123-10-070596-index.htm.","url":"https://asof.is/claim/clm_FBAE96E2C630","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"10,235,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FBAE96E2C630","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-Q/A Q2 FY2010, filed 2010-08-02"}},{"date":"2010-07-20","until":"2010-10-20","published":"2010-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,153,140,311 shares\", as of 2010-07-20 (until 2010-10-20). Claim clm_2A46B3B6816C, https://asof.is/claim/clm_2A46B3B6816C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310070596/0000950123-10-070596-index.htm.","url":"https://asof.is/claim/clm_2A46B3B6816C","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,153,140,311 shares","status":"superseded","assertable":true,"id":"clm_2A46B3B6816C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q/A Q2 FY2010, filed 2010-08-02"}},{"date":"2010-09-30","until":"2011-03-31","published":"2010-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,302,900,000 United States dollar\", as of 2010-09-30 (until 2011-03-31). Claim clm_37EF8BFF3C1E, https://asof.is/claim/clm_37EF8BFF3C1E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310097867/0000950123-10-097867-index.htm.","url":"https://asof.is/claim/clm_37EF8BFF3C1E","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,302,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_37EF8BFF3C1E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2010, filed 2010-10-29"}},{"date":"2010-09-30","until":"2011-03-31","published":"2010-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,219,800,000 United States dollar\", as of 2010-09-30 (until 2011-03-31). Claim clm_49B945AD669C, https://asof.is/claim/clm_49B945AD669C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310097867/0000950123-10-097867-index.htm.","url":"https://asof.is/claim/clm_49B945AD669C","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,219,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_49B945AD669C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2010, filed 2010-10-29"}},{"date":"2010-09-30","until":"2011-03-31","published":"2010-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,654,800,000 United States dollar\", as of 2010-09-30 (until 2011-03-31). Claim clm_4D8CE841EAC1, https://asof.is/claim/clm_4D8CE841EAC1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310097867/0000950123-10-097867-index.htm.","url":"https://asof.is/claim/clm_4D8CE841EAC1","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,654,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4D8CE841EAC1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2010, filed 2010-10-29"}},{"date":"2010-09-30","until":"2010-12-31","published":"2010-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 29,904,300,000 United States dollar\", as of 2010-09-30 (until 2010-12-31). Claim clm_57EC22604D75, https://asof.is/claim/clm_57EC22604D75, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310097867/0000950123-10-097867-index.htm.","url":"https://asof.is/claim/clm_57EC22604D75","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"29,904,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_57EC22604D75","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2010, filed 2010-10-29"}},{"date":"2010-09-30","until":"2010-12-31","published":"2010-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 12,405,500,000 United States dollar\", as of 2010-09-30 (until 2010-12-31). Claim clm_A6D50CE13C80, https://asof.is/claim/clm_A6D50CE13C80, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310097867/0000950123-10-097867-index.htm.","url":"https://asof.is/claim/clm_A6D50CE13C80","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"12,405,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A6D50CE13C80","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-Q Q3 FY2010, filed 2010-10-29"}},{"date":"2010-09-30","until":"2010-12-31","published":"2010-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 5,908,800,000 United States dollar\", as of 2010-09-30 (until 2010-12-31). Claim clm_D55EB81EF641, https://asof.is/claim/clm_D55EB81EF641, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310097867/0000950123-10-097867-index.htm.","url":"https://asof.is/claim/clm_D55EB81EF641","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"5,908,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D55EB81EF641","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2010, filed 2010-10-29"}},{"date":"2010-10-20","until":"2011-02-15","published":"2010-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,153,143,311 shares\", as of 2010-10-20 (until 2011-02-15). Claim clm_4EF303147BF7, https://asof.is/claim/clm_4EF303147BF7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000095012310097867/0000950123-10-097867-index.htm.","url":"https://asof.is/claim/clm_4EF303147BF7","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,153,143,311 shares","status":"superseded","assertable":true,"id":"clm_4EF303147BF7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2010, filed 2010-10-29"}},{"date":"2010-12-31","until":"2011-12-31","published":"2011-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company revenue: 23,076,000,000 United States dollar\", as of 2010-12-31 (until 2011-12-31). Claim clm_2164E9BDD211, https://asof.is/claim/clm_2164E9BDD211, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511041620/0001193125-11-041620-index.htm.","url":"https://asof.is/claim/clm_2164E9BDD211","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"23,076,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2164E9BDD211","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2010, filed 2011-02-22"}},{"date":"2010-12-31","until":"2011-03-31","published":"2014-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 12,420,300,000 United States dollar\", as of 2010-12-31 (until 2011-03-31). Claim clm_38907029577E, https://asof.is/claim/clm_38907029577E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000078/0000059478-14-000078-index.htm.","url":"https://asof.is/claim/clm_38907029577E","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"12,420,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_38907029577E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2013, filed 2014-02-19"}},{"date":"2010-12-31","until":"2011-12-31","published":"2011-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company net income: 5,069,500,000 United States dollar\", as of 2010-12-31 (until 2011-12-31). Claim clm_4BDBC4365AB7, https://asof.is/claim/clm_4BDBC4365AB7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511041620/0001193125-11-041620-index.htm.","url":"https://asof.is/claim/clm_4BDBC4365AB7","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"5,069,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4BDBC4365AB7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2010, filed 2011-02-22"}},{"date":"2010-12-31","until":"2011-03-31","published":"2011-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 31,001,400,000 United States dollar\", as of 2010-12-31 (until 2011-03-31). Claim clm_4CD8C1030C06, https://asof.is/claim/clm_4CD8C1030C06, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511041620/0001193125-11-041620-index.htm.","url":"https://asof.is/claim/clm_4CD8C1030C06","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"31,001,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4CD8C1030C06","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2010, filed 2011-02-22"}},{"date":"2010-12-31","until":"2011-03-31","published":"2011-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 5,993,200,000 United States dollar\", as of 2010-12-31 (until 2011-03-31). Claim clm_5A71EDBC0AD2, https://asof.is/claim/clm_5A71EDBC0AD2, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511041620/0001193125-11-041620-index.htm.","url":"https://asof.is/claim/clm_5A71EDBC0AD2","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"5,993,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5A71EDBC0AD2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2010, filed 2011-02-22"}},{"date":"2010-12-31","until":"2011-12-31","published":"2011-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company research and development: 4,884,200,000 United States dollar\", as of 2010-12-31 (until 2011-12-31). Claim clm_E5BECE5372F5, https://asof.is/claim/clm_E5BECE5372F5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511041620/0001193125-11-041620-index.htm.","url":"https://asof.is/claim/clm_E5BECE5372F5","accessed":"2026-11-08"},"kind":"money","predicate":"research_and_development","value":"4,884,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E5BECE5372F5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2010, filed 2011-02-22"}},{"date":"2011-02-15","until":"2011-04-20","published":"2011-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,157,664,779 shares\", as of 2011-02-15 (until 2011-04-20). Claim clm_2EAD3D4E1CDB, https://asof.is/claim/clm_2EAD3D4E1CDB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511041620/0001193125-11-041620-index.htm.","url":"https://asof.is/claim/clm_2EAD3D4E1CDB","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,157,664,779 shares","status":"superseded","assertable":true,"id":"clm_2EAD3D4E1CDB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2010, filed 2011-02-22"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,055,900,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_444313C9661E, https://asof.is/claim/clm_444313C9661E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511117877/0001193125-11-117877-index.htm.","url":"https://asof.is/claim/clm_444313C9661E","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,055,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_444313C9661E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2011, filed 2011-04-29"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 31,695,300,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_5A450E7581A9, https://asof.is/claim/clm_5A450E7581A9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511117877/0001193125-11-117877-index.htm.","url":"https://asof.is/claim/clm_5A450E7581A9","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"31,695,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5A450E7581A9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2011, filed 2011-04-29"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 6,506,400,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_A1E24BDCAA75, https://asof.is/claim/clm_A1E24BDCAA75, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511117877/0001193125-11-117877-index.htm.","url":"https://asof.is/claim/clm_A1E24BDCAA75","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"6,506,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A1E24BDCAA75","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2011, filed 2011-04-29"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,124,000,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_B28901D6C9E0, https://asof.is/claim/clm_B28901D6C9E0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511117877/0001193125-11-117877-index.htm.","url":"https://asof.is/claim/clm_B28901D6C9E0","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,124,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B28901D6C9E0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2011, filed 2011-04-29"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,839,200,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_D8537173D284, https://asof.is/claim/clm_D8537173D284, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511117877/0001193125-11-117877-index.htm.","url":"https://asof.is/claim/clm_D8537173D284","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,839,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D8537173D284","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2011, filed 2011-04-29"}},{"date":"2011-03-31","until":"2011-06-30","published":"2011-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 13,934,200,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_F3231A21A793, https://asof.is/claim/clm_F3231A21A793, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511117877/0001193125-11-117877-index.htm.","url":"https://asof.is/claim/clm_F3231A21A793","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"13,934,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F3231A21A793","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-Q Q1 FY2011, filed 2011-04-29"}},{"date":"2011-04-20","until":"2011-07-20","published":"2011-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,157,666,449 shares\", as of 2011-04-20 (until 2011-07-20). Claim clm_6A827F1F7429, https://asof.is/claim/clm_6A827F1F7429, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511117877/0001193125-11-117877-index.htm.","url":"https://asof.is/claim/clm_6A827F1F7429","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,157,666,449 shares","status":"superseded","assertable":true,"id":"clm_6A827F1F7429","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2011, filed 2011-04-29"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,197,300,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_008FDC208224, https://asof.is/claim/clm_008FDC208224, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511202740/0001193125-11-202740-index.htm.","url":"https://asof.is/claim/clm_008FDC208224","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,197,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_008FDC208224","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2011, filed 2011-07-29"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 14,277,000,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_04056C4340A0, https://asof.is/claim/clm_04056C4340A0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511202740/0001193125-11-202740-index.htm.","url":"https://asof.is/claim/clm_04056C4340A0","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"14,277,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_04056C4340A0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-Q Q2 FY2011, filed 2011-07-29"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 32,779,300,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_56266631D4EB, https://asof.is/claim/clm_56266631D4EB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511202740/0001193125-11-202740-index.htm.","url":"https://asof.is/claim/clm_56266631D4EB","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"32,779,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_56266631D4EB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2011, filed 2011-07-29"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,260,600,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_8B1DF12BB663, https://asof.is/claim/clm_8B1DF12BB663, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511202740/0001193125-11-202740-index.htm.","url":"https://asof.is/claim/clm_8B1DF12BB663","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,260,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8B1DF12BB663","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2011, filed 2011-07-29"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 6,113,500,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_B2819CA11725, https://asof.is/claim/clm_B2819CA11725, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511202740/0001193125-11-202740-index.htm.","url":"https://asof.is/claim/clm_B2819CA11725","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"6,113,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B2819CA11725","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2011, filed 2011-07-29"}},{"date":"2011-06-30","until":"2011-09-30","published":"2011-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 6,252,800,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_DC301C0F7A36, https://asof.is/claim/clm_DC301C0F7A36, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511202740/0001193125-11-202740-index.htm.","url":"https://asof.is/claim/clm_DC301C0F7A36","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"6,252,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DC301C0F7A36","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2011, filed 2011-07-29"}},{"date":"2011-07-20","until":"2011-10-20","published":"2011-07-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,157,688,685 shares\", as of 2011-07-20 (until 2011-10-20). Claim clm_BC1F6D19D227, https://asof.is/claim/clm_BC1F6D19D227, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511202740/0001193125-11-202740-index.htm.","url":"https://asof.is/claim/clm_BC1F6D19D227","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,157,688,685 shares","status":"superseded","assertable":true,"id":"clm_BC1F6D19D227","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2011, filed 2011-07-29"}},{"date":"2011-09-30","until":"2012-03-31","published":"2011-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,236,300,000 United States dollar\", as of 2011-09-30 (until 2012-03-31). Claim clm_354B7C6D61E5, https://asof.is/claim/clm_354B7C6D61E5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511286084/0001193125-11-286084-index.htm.","url":"https://asof.is/claim/clm_354B7C6D61E5","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,236,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_354B7C6D61E5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2011, filed 2011-10-28"}},{"date":"2011-09-30","until":"2011-12-31","published":"2011-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 15,057,900,000 United States dollar\", as of 2011-09-30 (until 2011-12-31). Claim clm_46A4D8518C6C, https://asof.is/claim/clm_46A4D8518C6C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511286084/0001193125-11-286084-index.htm.","url":"https://asof.is/claim/clm_46A4D8518C6C","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"15,057,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_46A4D8518C6C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-Q Q3 FY2011, filed 2011-10-28"}},{"date":"2011-09-30","until":"2012-03-31","published":"2011-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,280,900,000 United States dollar\", as of 2011-09-30 (until 2012-03-31). Claim clm_62421650D215, https://asof.is/claim/clm_62421650D215, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511286084/0001193125-11-286084-index.htm.","url":"https://asof.is/claim/clm_62421650D215","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,280,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_62421650D215","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2011, filed 2011-10-28"}},{"date":"2011-09-30","until":"2011-12-31","published":"2011-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 6,597,700,000 United States dollar\", as of 2011-09-30 (until 2011-12-31). Claim clm_791E44413C99, https://asof.is/claim/clm_791E44413C99, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511286084/0001193125-11-286084-index.htm.","url":"https://asof.is/claim/clm_791E44413C99","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"6,597,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_791E44413C99","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2011, filed 2011-10-28"}},{"date":"2011-09-30","until":"2012-03-31","published":"2011-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 6,147,900,000 United States dollar\", as of 2011-09-30 (until 2012-03-31). Claim clm_8942550E1D13, https://asof.is/claim/clm_8942550E1D13, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511286084/0001193125-11-286084-index.htm.","url":"https://asof.is/claim/clm_8942550E1D13","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"6,147,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8942550E1D13","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2011, filed 2011-10-28"}},{"date":"2011-09-30","until":"2011-12-31","published":"2011-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 33,042,200,000 United States dollar\", as of 2011-09-30 (until 2011-12-31). Claim clm_8A478ABF3F11, https://asof.is/claim/clm_8A478ABF3F11, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511286084/0001193125-11-286084-index.htm.","url":"https://asof.is/claim/clm_8A478ABF3F11","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"33,042,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8A478ABF3F11","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2011, filed 2011-10-28"}},{"date":"2011-10-20","until":"2012-02-15","published":"2011-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,157,762,135 shares\", as of 2011-10-20 (until 2012-02-15). Claim clm_8D6F78B317FE, https://asof.is/claim/clm_8D6F78B317FE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312511286084/0001193125-11-286084-index.htm.","url":"https://asof.is/claim/clm_8D6F78B317FE","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,157,762,135 shares","status":"superseded","assertable":true,"id":"clm_8D6F78B317FE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2011, filed 2011-10-28"}},{"date":"2011-12-31","until":"2012-03-31","published":"2012-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 5,922,500,000 United States dollar\", as of 2011-12-31 (until 2012-03-31). Claim clm_1B2574BD7DC9, https://asof.is/claim/clm_1B2574BD7DC9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312512078393/0001193125-12-078393-index.htm.","url":"https://asof.is/claim/clm_1B2574BD7DC9","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"5,922,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1B2574BD7DC9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2011, filed 2012-02-24"}},{"date":"2011-12-31","until":"2012-03-31","published":"2014-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 13,541,700,000 United States dollar\", as of 2011-12-31 (until 2012-03-31). Claim clm_4C30A8195523, https://asof.is/claim/clm_4C30A8195523, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000078/0000059478-14-000078-index.htm.","url":"https://asof.is/claim/clm_4C30A8195523","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"13,541,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4C30A8195523","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2013, filed 2014-02-19"}},{"date":"2011-12-31","until":"2012-12-31","published":"2012-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company net income: 4,347,700,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_7E497C262CA8, https://asof.is/claim/clm_7E497C262CA8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312512078393/0001193125-12-078393-index.htm.","url":"https://asof.is/claim/clm_7E497C262CA8","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"4,347,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7E497C262CA8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2011, filed 2012-02-24"}},{"date":"2011-12-31","until":"2012-12-31","published":"2012-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company research and development: 5,020,800,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_965E7901CE0F, https://asof.is/claim/clm_965E7901CE0F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312512078393/0001193125-12-078393-index.htm.","url":"https://asof.is/claim/clm_965E7901CE0F","accessed":"2026-11-08"},"kind":"money","predicate":"research_and_development","value":"5,020,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_965E7901CE0F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2011, filed 2012-02-24"}},{"date":"2011-12-31","until":"2012-03-31","published":"2012-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 33,659,800,000 United States dollar\", as of 2011-12-31 (until 2012-03-31). Claim clm_A0CD20471FEE, https://asof.is/claim/clm_A0CD20471FEE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312512078393/0001193125-12-078393-index.htm.","url":"https://asof.is/claim/clm_A0CD20471FEE","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"33,659,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A0CD20471FEE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2011, filed 2012-02-24"}},{"date":"2011-12-31","until":"2012-12-31","published":"2012-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company revenue: 24,286,500,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_BF9624252D1F, https://asof.is/claim/clm_BF9624252D1F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312512078393/0001193125-12-078393-index.htm.","url":"https://asof.is/claim/clm_BF9624252D1F","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"24,286,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BF9624252D1F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2011, filed 2012-02-24"}},{"date":"2012-02-15","until":"2012-04-20","published":"2012-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,160,406,840 shares\", as of 2012-02-15 (until 2012-04-20). Claim clm_98D3F4CB333B, https://asof.is/claim/clm_98D3F4CB333B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312512078393/0001193125-12-078393-index.htm.","url":"https://asof.is/claim/clm_98D3F4CB333B","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,160,406,840 shares","status":"superseded","assertable":true,"id":"clm_98D3F4CB333B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2011, filed 2012-02-24"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 14,822,600,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_0229E1C0F88C, https://asof.is/claim/clm_0229E1C0F88C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312512195656/0001193125-12-195656-index.htm.","url":"https://asof.is/claim/clm_0229E1C0F88C","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"14,822,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0229E1C0F88C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-Q Q1 FY2012, filed 2012-04-30"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,151,500,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_484485049F9B, https://asof.is/claim/clm_484485049F9B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312512195656/0001193125-12-195656-index.htm.","url":"https://asof.is/claim/clm_484485049F9B","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,151,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_484485049F9B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2012, filed 2012-04-30"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 4,122,200,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_536151C257D4, https://asof.is/claim/clm_536151C257D4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312512195656/0001193125-12-195656-index.htm.","url":"https://asof.is/claim/clm_536151C257D4","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"4,122,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_536151C257D4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2012, filed 2012-04-30"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 32,238,200,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_74CB0764DE87, https://asof.is/claim/clm_74CB0764DE87, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312512195656/0001193125-12-195656-index.htm.","url":"https://asof.is/claim/clm_74CB0764DE87","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"32,238,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_74CB0764DE87","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2012, filed 2012-04-30"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,602,000,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_7903628E4764, https://asof.is/claim/clm_7903628E4764, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312512195656/0001193125-12-195656-index.htm.","url":"https://asof.is/claim/clm_7903628E4764","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,602,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7903628E4764","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2012, filed 2012-04-30"}},{"date":"2012-03-31","until":"2012-06-30","published":"2012-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,011,100,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_DDE62BAA81E2, https://asof.is/claim/clm_DDE62BAA81E2, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312512195656/0001193125-12-195656-index.htm.","url":"https://asof.is/claim/clm_DDE62BAA81E2","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,011,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DDE62BAA81E2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2012, filed 2012-04-30"}},{"date":"2012-04-20","until":"2012-07-20","published":"2012-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,160,415,307 shares\", as of 2012-04-20 (until 2012-07-20). Claim clm_DAEB0FB8113F, https://asof.is/claim/clm_DAEB0FB8113F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000119312512195656/0001193125-12-195656-index.htm.","url":"https://asof.is/claim/clm_DAEB0FB8113F","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,160,415,307 shares","status":"superseded","assertable":true,"id":"clm_DAEB0FB8113F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2012, filed 2012-04-30"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-07-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 4,345,800,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_026D54438B59, https://asof.is/claim/clm_026D54438B59, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947812000006/0000059478-12-000006-index.htm.","url":"https://asof.is/claim/clm_026D54438B59","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"4,345,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_026D54438B59","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2012, filed 2012-07-27"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-07-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,600,700,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_5DAD0E6A0EE5, https://asof.is/claim/clm_5DAD0E6A0EE5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947812000006/0000059478-12-000006-index.htm.","url":"https://asof.is/claim/clm_5DAD0E6A0EE5","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,600,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5DAD0E6A0EE5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2012, filed 2012-07-27"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-07-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,320,700,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_60F07D90B8A9, https://asof.is/claim/clm_60F07D90B8A9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947812000006/0000059478-12-000006-index.htm.","url":"https://asof.is/claim/clm_60F07D90B8A9","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,320,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_60F07D90B8A9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2012, filed 2012-07-27"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-07-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 14,307,900,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_66BC72EF2E29, https://asof.is/claim/clm_66BC72EF2E29, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947812000006/0000059478-12-000006-index.htm.","url":"https://asof.is/claim/clm_66BC72EF2E29","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"14,307,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_66BC72EF2E29","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-Q Q2 FY2012, filed 2012-07-27"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-07-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 31,812,600,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_99236EECA95B, https://asof.is/claim/clm_99236EECA95B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947812000006/0000059478-12-000006-index.htm.","url":"https://asof.is/claim/clm_99236EECA95B","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"31,812,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_99236EECA95B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2012, filed 2012-07-27"}},{"date":"2012-06-30","until":"2012-09-30","published":"2012-07-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 923,600,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_FD077BD0D902, https://asof.is/claim/clm_FD077BD0D902, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947812000006/0000059478-12-000006-index.htm.","url":"https://asof.is/claim/clm_FD077BD0D902","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"923,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FD077BD0D902","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2012, filed 2012-07-27"}},{"date":"2012-07-20","until":"2012-10-20","published":"2012-07-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,160,425,459 shares\", as of 2012-07-20 (until 2012-10-20). Claim clm_E5115E989619, https://asof.is/claim/clm_E5115E989619, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947812000006/0000059478-12-000006-index.htm.","url":"https://asof.is/claim/clm_E5115E989619","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,160,425,459 shares","status":"superseded","assertable":true,"id":"clm_E5115E989619","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2012, filed 2012-07-27"}},{"date":"2012-09-30","until":"2013-03-31","published":"2012-10-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,326,600,000 United States dollar\", as of 2012-09-30 (until 2013-03-31). Claim clm_326641396B5E, https://asof.is/claim/clm_326641396B5E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947812000021/0000059478-12-000021-index.htm.","url":"https://asof.is/claim/clm_326641396B5E","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,326,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_326641396B5E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2012, filed 2012-10-26"}},{"date":"2012-09-30","until":"2012-12-31","published":"2012-10-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 34,321,000,000 United States dollar\", as of 2012-09-30 (until 2012-12-31). Claim clm_485295C4EFF2, https://asof.is/claim/clm_485295C4EFF2, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947812000021/0000059478-12-000021-index.htm.","url":"https://asof.is/claim/clm_485295C4EFF2","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"34,321,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_485295C4EFF2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2012, filed 2012-10-26"}},{"date":"2012-09-30","until":"2013-03-31","published":"2012-10-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,443,300,000 United States dollar\", as of 2012-09-30 (until 2013-03-31). Claim clm_911654133F1A, https://asof.is/claim/clm_911654133F1A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947812000021/0000059478-12-000021-index.htm.","url":"https://asof.is/claim/clm_911654133F1A","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,443,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_911654133F1A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2012, filed 2012-10-26"}},{"date":"2012-09-30","until":"2013-03-31","published":"2012-10-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,342,800,000 United States dollar\", as of 2012-09-30 (until 2013-03-31). Claim clm_916A4076C233, https://asof.is/claim/clm_916A4076C233, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947812000021/0000059478-12-000021-index.htm.","url":"https://asof.is/claim/clm_916A4076C233","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,342,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_916A4076C233","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2012, filed 2012-10-26"}},{"date":"2012-09-30","until":"2012-12-31","published":"2012-10-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 5,319,200,000 United States dollar\", as of 2012-09-30 (until 2012-12-31). Claim clm_E6EA3ECD40CD, https://asof.is/claim/clm_E6EA3ECD40CD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947812000021/0000059478-12-000021-index.htm.","url":"https://asof.is/claim/clm_E6EA3ECD40CD","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"5,319,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E6EA3ECD40CD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2012, filed 2012-10-26"}},{"date":"2012-09-30","until":"2012-12-31","published":"2012-10-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 16,056,900,000 United States dollar\", as of 2012-09-30 (until 2012-12-31). Claim clm_F69758EEF222, https://asof.is/claim/clm_F69758EEF222, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947812000021/0000059478-12-000021-index.htm.","url":"https://asof.is/claim/clm_F69758EEF222","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"16,056,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F69758EEF222","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-Q Q3 FY2012, filed 2012-10-26"}},{"date":"2012-10-20","until":"2013-02-15","published":"2012-10-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,160,452,507 shares\", as of 2012-10-20 (until 2013-02-15). Claim clm_68696D5895F1, https://asof.is/claim/clm_68696D5895F1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947812000021/0000059478-12-000021-index.htm.","url":"https://asof.is/claim/clm_68696D5895F1","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,160,452,507 shares","status":"superseded","assertable":true,"id":"clm_68696D5895F1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2012, filed 2012-10-26"}},{"date":"2012-12-31","until":"2013-12-31","published":"2013-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company research and development: 5,278,100,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_1B4BD9A59709, https://asof.is/claim/clm_1B4BD9A59709, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000007/0000059478-13-000007-index.htm.","url":"https://asof.is/claim/clm_1B4BD9A59709","accessed":"2026-11-08"},"kind":"money","predicate":"research_and_development","value":"5,278,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1B4BD9A59709","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2012, filed 2013-02-21"}},{"date":"2012-12-31","until":"2013-03-31","published":"2013-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 4,018,800,000 United States dollar\", as of 2012-12-31 (until 2013-03-31). Claim clm_2B4A9BAB1058, https://asof.is/claim/clm_2B4A9BAB1058, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000007/0000059478-13-000007-index.htm.","url":"https://asof.is/claim/clm_2B4A9BAB1058","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"4,018,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2B4A9BAB1058","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2012, filed 2013-02-21"}},{"date":"2012-12-31","until":"2013-12-31","published":"2013-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company net income: 4,088,600,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_592E3DCB062C, https://asof.is/claim/clm_592E3DCB062C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000007/0000059478-13-000007-index.htm.","url":"https://asof.is/claim/clm_592E3DCB062C","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"4,088,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_592E3DCB062C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2012, filed 2013-02-21"}},{"date":"2012-12-31","until":"2013-12-31","published":"2013-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company revenue: 22,603,400,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_8E230B90B165, https://asof.is/claim/clm_8E230B90B165, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000007/0000059478-13-000007-index.htm.","url":"https://asof.is/claim/clm_8E230B90B165","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"22,603,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8E230B90B165","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2012, filed 2013-02-21"}},{"date":"2012-12-31","until":"2013-03-31","published":"2013-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 34,398,900,000 United States dollar\", as of 2012-12-31 (until 2013-03-31). Claim clm_CB104F41D380, https://asof.is/claim/clm_CB104F41D380, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000007/0000059478-13-000007-index.htm.","url":"https://asof.is/claim/clm_CB104F41D380","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"34,398,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CB104F41D380","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2012, filed 2013-02-21"}},{"date":"2012-12-31","until":"2013-03-31","published":"2014-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 14,765,200,000 United States dollar\", as of 2012-12-31 (until 2013-03-31). Claim clm_FB9C859803DD, https://asof.is/claim/clm_FB9C859803DD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000078/0000059478-14-000078-index.htm.","url":"https://asof.is/claim/clm_FB9C859803DD","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"14,765,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FB9C859803DD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2013, filed 2014-02-19"}},{"date":"2013-02-15","until":"2013-04-20","published":"2013-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,134,411,762 shares\", as of 2013-02-15 (until 2013-04-20). Claim clm_31DF8C9FFA10, https://asof.is/claim/clm_31DF8C9FFA10, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000007/0000059478-13-000007-index.htm.","url":"https://asof.is/claim/clm_31DF8C9FFA10","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,134,411,762 shares","status":"superseded","assertable":true,"id":"clm_31DF8C9FFA10","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2012, filed 2013-02-21"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-04-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,602,000,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_0690B5F615D3, https://asof.is/claim/clm_0690B5F615D3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000019/0000059478-13-000019-index.htm.","url":"https://asof.is/claim/clm_0690B5F615D3","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,602,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0690B5F615D3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2013, filed 2013-04-26"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-04-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,936,600,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_1F2201F2D0BD, https://asof.is/claim/clm_1F2201F2D0BD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000019/0000059478-13-000019-index.htm.","url":"https://asof.is/claim/clm_1F2201F2D0BD","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,936,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1F2201F2D0BD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2013, filed 2013-04-26"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-04-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 14,955,600,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_84981FD25199, https://asof.is/claim/clm_84981FD25199, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000019/0000059478-13-000019-index.htm.","url":"https://asof.is/claim/clm_84981FD25199","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"14,955,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_84981FD25199","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-Q Q1 FY2013, filed 2013-04-26"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-04-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,348,100,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_D1081C21953D, https://asof.is/claim/clm_D1081C21953D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000019/0000059478-13-000019-index.htm.","url":"https://asof.is/claim/clm_D1081C21953D","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,348,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D1081C21953D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2013, filed 2013-04-26"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-04-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,548,000,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_D4B25CE8BA78, https://asof.is/claim/clm_D4B25CE8BA78, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000019/0000059478-13-000019-index.htm.","url":"https://asof.is/claim/clm_D4B25CE8BA78","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,548,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D4B25CE8BA78","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2013, filed 2013-04-26"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-04-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 32,300,100,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_F659FE767693, https://asof.is/claim/clm_F659FE767693, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000019/0000059478-13-000019-index.htm.","url":"https://asof.is/claim/clm_F659FE767693","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"32,300,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F659FE767693","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2013, filed 2013-04-26"}},{"date":"2013-04-20","until":"2013-07-20","published":"2013-04-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,126,561,464 shares\", as of 2013-04-20 (until 2013-07-20). Claim clm_2ECD2538ABDF, https://asof.is/claim/clm_2ECD2538ABDF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000019/0000059478-13-000019-index.htm.","url":"https://asof.is/claim/clm_2ECD2538ABDF","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,126,561,464 shares","status":"superseded","assertable":true,"id":"clm_2ECD2538ABDF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2013, filed 2013-04-26"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-07-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 15,236,400,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_1701758C9C6B, https://asof.is/claim/clm_1701758C9C6B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000043/0000059478-13-000043-index.htm.","url":"https://asof.is/claim/clm_1701758C9C6B","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"15,236,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1701758C9C6B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-Q Q2 FY2013, filed 2013-07-26"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-07-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,786,500,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_1EFA1709BF1A, https://asof.is/claim/clm_1EFA1709BF1A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000043/0000059478-13-000043-index.htm.","url":"https://asof.is/claim/clm_1EFA1709BF1A","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,786,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1EFA1709BF1A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2013, filed 2013-07-26"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-07-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,929,700,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_3FC6922ADF8C, https://asof.is/claim/clm_3FC6922ADF8C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000043/0000059478-13-000043-index.htm.","url":"https://asof.is/claim/clm_3FC6922ADF8C","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,929,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3FC6922ADF8C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2013, filed 2013-07-26"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-07-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,206,200,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_60291CAA51AF, https://asof.is/claim/clm_60291CAA51AF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000043/0000059478-13-000043-index.htm.","url":"https://asof.is/claim/clm_60291CAA51AF","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,206,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_60291CAA51AF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2013, filed 2013-07-26"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-07-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 33,226,000,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_CBF31B7F88E5, https://asof.is/claim/clm_CBF31B7F88E5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000043/0000059478-13-000043-index.htm.","url":"https://asof.is/claim/clm_CBF31B7F88E5","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"33,226,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CBF31B7F88E5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2013, filed 2013-07-26"}},{"date":"2013-06-30","until":"2013-09-30","published":"2013-07-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,330,400,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_F933691E99F4, https://asof.is/claim/clm_F933691E99F4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000043/0000059478-13-000043-index.htm.","url":"https://asof.is/claim/clm_F933691E99F4","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,330,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F933691E99F4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2013, filed 2013-07-26"}},{"date":"2013-07-20","until":"2013-10-23","published":"2013-07-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,126,637,846 shares\", as of 2013-07-20 (until 2013-10-23). Claim clm_075381BC33FC, https://asof.is/claim/clm_075381BC33FC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000043/0000059478-13-000043-index.htm.","url":"https://asof.is/claim/clm_075381BC33FC","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,126,637,846 shares","status":"superseded","assertable":true,"id":"clm_075381BC33FC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2013, filed 2013-07-26"}},{"date":"2013-09-30","until":"2013-12-31","published":"2013-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 33,965,600,000 United States dollar\", as of 2013-09-30 (until 2013-12-31). Claim clm_39E899BCF868, https://asof.is/claim/clm_39E899BCF868, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000057/0000059478-13-000057-index.htm.","url":"https://asof.is/claim/clm_39E899BCF868","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"33,965,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_39E899BCF868","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2013, filed 2013-10-30"}},{"date":"2013-09-30","until":"2014-03-31","published":"2013-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,377,400,000 United States dollar\", as of 2013-09-30 (until 2014-03-31). Claim clm_4E41FE1D526A, https://asof.is/claim/clm_4E41FE1D526A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000057/0000059478-13-000057-index.htm.","url":"https://asof.is/claim/clm_4E41FE1D526A","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,377,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4E41FE1D526A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2013, filed 2013-10-30"}},{"date":"2013-09-30","until":"2014-03-31","published":"2013-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,772,600,000 United States dollar\", as of 2013-09-30 (until 2014-03-31). Claim clm_843FCDB40589, https://asof.is/claim/clm_843FCDB40589, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000057/0000059478-13-000057-index.htm.","url":"https://asof.is/claim/clm_843FCDB40589","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,772,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_843FCDB40589","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2013, filed 2013-10-30"}},{"date":"2013-09-30","until":"2013-12-31","published":"2013-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 4,368,900,000 United States dollar\", as of 2013-09-30 (until 2013-12-31). Claim clm_AA58254D76F9, https://asof.is/claim/clm_AA58254D76F9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000057/0000059478-13-000057-index.htm.","url":"https://asof.is/claim/clm_AA58254D76F9","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"4,368,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AA58254D76F9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2013, filed 2013-10-30"}},{"date":"2013-09-30","until":"2014-03-31","published":"2013-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,203,100,000 United States dollar\", as of 2013-09-30 (until 2014-03-31). Claim clm_BFE79E4C8CBA, https://asof.is/claim/clm_BFE79E4C8CBA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000057/0000059478-13-000057-index.htm.","url":"https://asof.is/claim/clm_BFE79E4C8CBA","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,203,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BFE79E4C8CBA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2013, filed 2013-10-30"}},{"date":"2013-09-30","until":"2013-12-31","published":"2013-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 16,896,100,000 United States dollar\", as of 2013-09-30 (until 2013-12-31). Claim clm_EEEAB419DCCD, https://asof.is/claim/clm_EEEAB419DCCD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000057/0000059478-13-000057-index.htm.","url":"https://asof.is/claim/clm_EEEAB419DCCD","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"16,896,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EEEAB419DCCD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-Q Q3 FY2013, filed 2013-10-30"}},{"date":"2013-10-23","until":"2014-02-14","published":"2013-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,126,649,615 shares\", as of 2013-10-23 (until 2014-02-14). Claim clm_68E1EE01EC17, https://asof.is/claim/clm_68E1EE01EC17, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947813000057/0000059478-13-000057-index.htm.","url":"https://asof.is/claim/clm_68E1EE01EC17","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,126,649,615 shares","status":"superseded","assertable":true,"id":"clm_68E1EE01EC17","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2013, filed 2013-10-30"}},{"date":"2013-12-31","until":"2014-12-31","published":"2014-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company net income: 4,684,800,000 United States dollar\", as of 2013-12-31 (until 2014-12-31). Claim clm_172E66143A90, https://asof.is/claim/clm_172E66143A90, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000078/0000059478-14-000078-index.htm.","url":"https://asof.is/claim/clm_172E66143A90","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"4,684,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_172E66143A90","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2013, filed 2014-02-19"}},{"date":"2013-12-31","until":"2014-03-31","published":"2014-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,830,200,000 United States dollar\", as of 2013-12-31 (until 2014-03-31). Claim clm_2F65246E9FDA, https://asof.is/claim/clm_2F65246E9FDA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000078/0000059478-14-000078-index.htm.","url":"https://asof.is/claim/clm_2F65246E9FDA","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,830,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2F65246E9FDA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2013, filed 2014-02-19"}},{"date":"2013-12-31","until":"2014-03-31","published":"2014-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 17,631,400,000 United States dollar\", as of 2013-12-31 (until 2014-03-31). Claim clm_449F1D02A97D, https://asof.is/claim/clm_449F1D02A97D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000078/0000059478-14-000078-index.htm.","url":"https://asof.is/claim/clm_449F1D02A97D","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"17,631,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_449F1D02A97D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2013, filed 2014-02-19"}},{"date":"2013-12-31","until":"2014-03-31","published":"2014-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 35,248,700,000 United States dollar\", as of 2013-12-31 (until 2014-03-31). Claim clm_5BEEA4B8561C, https://asof.is/claim/clm_5BEEA4B8561C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000078/0000059478-14-000078-index.htm.","url":"https://asof.is/claim/clm_5BEEA4B8561C","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"35,248,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5BEEA4B8561C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2013, filed 2014-02-19"}},{"date":"2013-12-31","until":"2014-12-31","published":"2014-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company revenue: 23,113,100,000 United States dollar\", as of 2013-12-31 (until 2014-12-31). Claim clm_8F9AC59BE835, https://asof.is/claim/clm_8F9AC59BE835, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000078/0000059478-14-000078-index.htm.","url":"https://asof.is/claim/clm_8F9AC59BE835","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"23,113,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8F9AC59BE835","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2013, filed 2014-02-19"}},{"date":"2013-12-31","until":"2014-12-31","published":"2014-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company research and development: 5,531,300,000 United States dollar\", as of 2013-12-31 (until 2014-12-31). Claim clm_ADD13B3620DD, https://asof.is/claim/clm_ADD13B3620DD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000078/0000059478-14-000078-index.htm.","url":"https://asof.is/claim/clm_ADD13B3620DD","accessed":"2026-11-08"},"kind":"money","predicate":"research_and_development","value":"5,531,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_ADD13B3620DD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2013, filed 2014-02-19"}},{"date":"2014-02-14","until":"2014-04-21","published":"2014-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,119,713,084 shares\", as of 2014-02-14 (until 2014-04-21). Claim clm_D846AC4397FC, https://asof.is/claim/clm_D846AC4397FC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000078/0000059478-14-000078-index.htm.","url":"https://asof.is/claim/clm_D846AC4397FC","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,119,713,084 shares","status":"superseded","assertable":true,"id":"clm_D846AC4397FC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2013, filed 2014-02-19"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 18,338,100,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_06455B93E953, https://asof.is/claim/clm_06455B93E953, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000102/0000059478-14-000102-index.htm.","url":"https://asof.is/claim/clm_06455B93E953","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"18,338,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_06455B93E953","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2014, filed 2014-04-28"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,109,300,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_2E0D01292DDE, https://asof.is/claim/clm_2E0D01292DDE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000102/0000059478-14-000102-index.htm.","url":"https://asof.is/claim/clm_2E0D01292DDE","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,109,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2E0D01292DDE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2014, filed 2014-04-28"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 727,900,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_358CB722EF06, https://asof.is/claim/clm_358CB722EF06, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000102/0000059478-14-000102-index.htm.","url":"https://asof.is/claim/clm_358CB722EF06","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"727,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_358CB722EF06","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2014, filed 2014-04-28"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,888,000,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_51D0379CC24E, https://asof.is/claim/clm_51D0379CC24E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000102/0000059478-14-000102-index.htm.","url":"https://asof.is/claim/clm_51D0379CC24E","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,888,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_51D0379CC24E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2014, filed 2014-04-28"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 34,756,900,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_9DDA60F84708, https://asof.is/claim/clm_9DDA60F84708, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000102/0000059478-14-000102-index.htm.","url":"https://asof.is/claim/clm_9DDA60F84708","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"34,756,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9DDA60F84708","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2014, filed 2014-04-28"}},{"date":"2014-03-31","until":"2014-06-30","published":"2014-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 4,683,100,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_E805A9930871, https://asof.is/claim/clm_E805A9930871, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000102/0000059478-14-000102-index.htm.","url":"https://asof.is/claim/clm_E805A9930871","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"4,683,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E805A9930871","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2014, filed 2014-04-28"}},{"date":"2014-04-21","until":"2014-07-21","published":"2014-04-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,119,451,042 shares\", as of 2014-04-21 (until 2014-07-21). Claim clm_9F6D0BBC5F93, https://asof.is/claim/clm_9F6D0BBC5F93, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000102/0000059478-14-000102-index.htm.","url":"https://asof.is/claim/clm_9F6D0BBC5F93","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,119,451,042 shares","status":"superseded","assertable":true,"id":"clm_9F6D0BBC5F93","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2014, filed 2014-04-28"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 4,935,600,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_104129ED0A97, https://asof.is/claim/clm_104129ED0A97, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000129/0000059478-14-000129-index.htm.","url":"https://asof.is/claim/clm_104129ED0A97","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"4,935,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_104129ED0A97","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2014, filed 2014-07-28"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,195,400,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_4659F2118ED9, https://asof.is/claim/clm_4659F2118ED9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000129/0000059478-14-000129-index.htm.","url":"https://asof.is/claim/clm_4659F2118ED9","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,195,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4659F2118ED9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2014, filed 2014-07-28"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 733,500,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_78EB084A9EA9, https://asof.is/claim/clm_78EB084A9EA9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000129/0000059478-14-000129-index.htm.","url":"https://asof.is/claim/clm_78EB084A9EA9","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"733,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_78EB084A9EA9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2014, filed 2014-07-28"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,765,700,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_7B542E4AE18B, https://asof.is/claim/clm_7B542E4AE18B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000129/0000059478-14-000129-index.htm.","url":"https://asof.is/claim/clm_7B542E4AE18B","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,765,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7B542E4AE18B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2014, filed 2014-07-28"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 17,983,700,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_BA7FB06172CD, https://asof.is/claim/clm_BA7FB06172CD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000129/0000059478-14-000129-index.htm.","url":"https://asof.is/claim/clm_BA7FB06172CD","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"17,983,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BA7FB06172CD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2014, filed 2014-07-28"}},{"date":"2014-06-30","until":"2014-09-30","published":"2014-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 35,018,400,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_FB670F4A5538, https://asof.is/claim/clm_FB670F4A5538, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000129/0000059478-14-000129-index.htm.","url":"https://asof.is/claim/clm_FB670F4A5538","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"35,018,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FB670F4A5538","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2014, filed 2014-07-28"}},{"date":"2014-07-21","until":"2014-10-20","published":"2014-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,117,308,330 shares\", as of 2014-07-21 (until 2014-10-20). Claim clm_11E3240141BF, https://asof.is/claim/clm_11E3240141BF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000129/0000059478-14-000129-index.htm.","url":"https://asof.is/claim/clm_11E3240141BF","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,117,308,330 shares","status":"superseded","assertable":true,"id":"clm_11E3240141BF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2014, filed 2014-07-28"}},{"date":"2014-09-30","until":"2015-03-31","published":"2014-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 4,875,600,000 United States dollar\", as of 2014-09-30 (until 2015-03-31). Claim clm_19B3061EB704, https://asof.is/claim/clm_19B3061EB704, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000169/0000059478-14-000169-index.htm.","url":"https://asof.is/claim/clm_19B3061EB704","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"4,875,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_19B3061EB704","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2014, filed 2014-10-29"}},{"date":"2014-09-30","until":"2014-12-31","published":"2014-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 34,648,800,000 United States dollar\", as of 2014-09-30 (until 2014-12-31). Claim clm_47020DB33D7E, https://asof.is/claim/clm_47020DB33D7E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000169/0000059478-14-000169-index.htm.","url":"https://asof.is/claim/clm_47020DB33D7E","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"34,648,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_47020DB33D7E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2014, filed 2014-10-29"}},{"date":"2014-09-30","until":"2014-12-31","published":"2014-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 17,669,300,000 United States dollar\", as of 2014-09-30 (until 2014-12-31). Claim clm_570B41055A07, https://asof.is/claim/clm_570B41055A07, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000169/0000059478-14-000169-index.htm.","url":"https://asof.is/claim/clm_570B41055A07","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"17,669,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_570B41055A07","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2014, filed 2014-10-29"}},{"date":"2014-09-30","until":"2015-03-31","published":"2014-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 500,600,000 United States dollar\", as of 2014-09-30 (until 2015-03-31). Claim clm_9A91A4856B27, https://asof.is/claim/clm_9A91A4856B27, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000169/0000059478-14-000169-index.htm.","url":"https://asof.is/claim/clm_9A91A4856B27","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"500,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9A91A4856B27","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2014, filed 2014-10-29"}},{"date":"2014-09-30","until":"2014-12-31","published":"2014-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,165,800,000 United States dollar\", as of 2014-09-30 (until 2014-12-31). Claim clm_B3A15581AD33, https://asof.is/claim/clm_B3A15581AD33, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000169/0000059478-14-000169-index.htm.","url":"https://asof.is/claim/clm_B3A15581AD33","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,165,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B3A15581AD33","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2014, filed 2014-10-29"}},{"date":"2014-09-30","until":"2015-03-31","published":"2014-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,243,200,000 United States dollar\", as of 2014-09-30 (until 2015-03-31). Claim clm_FBB910195E3D, https://asof.is/claim/clm_FBB910195E3D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000169/0000059478-14-000169-index.htm.","url":"https://asof.is/claim/clm_FBB910195E3D","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,243,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FBB910195E3D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2014, filed 2014-10-29"}},{"date":"2014-10-20","until":"2015-02-13","published":"2014-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,113,429,817 shares\", as of 2014-10-20 (until 2015-02-13). Claim clm_5E5FEE19FF6E, https://asof.is/claim/clm_5E5FEE19FF6E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947814000169/0000059478-14-000169-index.htm.","url":"https://asof.is/claim/clm_5E5FEE19FF6E","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,113,429,817 shares","status":"superseded","assertable":true,"id":"clm_5E5FEE19FF6E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2014, filed 2014-10-29"}},{"date":"2014-12-31","until":"2015-03-31","published":"2015-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 15,373,200,000 United States dollar\", as of 2014-12-31 (until 2015-03-31). Claim clm_1643AAEFAE6E, https://asof.is/claim/clm_1643AAEFAE6E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000100/0000059478-15-000100-index.htm.","url":"https://asof.is/claim/clm_1643AAEFAE6E","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"15,373,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1643AAEFAE6E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2014, filed 2015-02-19"}},{"date":"2014-12-31","until":"2015-03-31","published":"2015-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,871,600,000 United States dollar\", as of 2014-12-31 (until 2015-03-31). Claim clm_7595457A53B3, https://asof.is/claim/clm_7595457A53B3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000100/0000059478-15-000100-index.htm.","url":"https://asof.is/claim/clm_7595457A53B3","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,871,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7595457A53B3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2014, filed 2015-02-19"}},{"date":"2014-12-31","until":"2015-12-31","published":"2015-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company net income: 2,390,500,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_822B542164C0, https://asof.is/claim/clm_822B542164C0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000100/0000059478-15-000100-index.htm.","url":"https://asof.is/claim/clm_822B542164C0","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"2,390,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_822B542164C0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2014, filed 2015-02-19"}},{"date":"2014-12-31","until":"2015-12-31","published":"2015-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company research and development: 4,733,600,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_8C0CCBB2961E, https://asof.is/claim/clm_8C0CCBB2961E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000100/0000059478-15-000100-index.htm.","url":"https://asof.is/claim/clm_8C0CCBB2961E","accessed":"2026-11-08"},"kind":"money","predicate":"research_and_development","value":"4,733,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8C0CCBB2961E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2014, filed 2015-02-19"}},{"date":"2014-12-31","until":"2015-12-31","published":"2015-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company revenue: 19,615,600,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_931AAE69B168, https://asof.is/claim/clm_931AAE69B168, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000100/0000059478-15-000100-index.htm.","url":"https://asof.is/claim/clm_931AAE69B168","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"19,615,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_931AAE69B168","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2014, filed 2015-02-19"}},{"date":"2014-12-31","until":"2015-03-31","published":"2015-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 37,178,200,000 United States dollar\", as of 2014-12-31 (until 2015-03-31). Claim clm_FB9524B17425, https://asof.is/claim/clm_FB9524B17425, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000100/0000059478-15-000100-index.htm.","url":"https://asof.is/claim/clm_FB9524B17425","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"37,178,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FB9524B17425","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2014, filed 2015-02-19"}},{"date":"2015-02-13","until":"2015-04-20","published":"2015-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,111,103,942 shares\", as of 2015-02-13 (until 2015-04-20). Claim clm_5645E18EB230, https://asof.is/claim/clm_5645E18EB230, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000100/0000059478-15-000100-index.htm.","url":"https://asof.is/claim/clm_5645E18EB230","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,111,103,942 shares","status":"superseded","assertable":true,"id":"clm_5645E18EB230","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2014, filed 2015-02-19"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 4,644,700,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_5E48B7152576, https://asof.is/claim/clm_5E48B7152576, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000132/0000059478-15-000132-index.htm.","url":"https://asof.is/claim/clm_5E48B7152576","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"4,644,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5E48B7152576","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2015, filed 2015-04-30"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 35,653,900,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_619A4B786053, https://asof.is/claim/clm_619A4B786053, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000132/0000059478-15-000132-index.htm.","url":"https://asof.is/claim/clm_619A4B786053","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"35,653,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_619A4B786053","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2015, filed 2015-04-30"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 14,919,800,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_63D5F3BF0AB6, https://asof.is/claim/clm_63D5F3BF0AB6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000132/0000059478-15-000132-index.htm.","url":"https://asof.is/claim/clm_63D5F3BF0AB6","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"14,919,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_63D5F3BF0AB6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2015, filed 2015-04-30"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 529,500,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_69787323BA17, https://asof.is/claim/clm_69787323BA17, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000132/0000059478-15-000132-index.htm.","url":"https://asof.is/claim/clm_69787323BA17","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"529,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_69787323BA17","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2015, filed 2015-04-30"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,064,800,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_8290EEB5A3E8, https://asof.is/claim/clm_8290EEB5A3E8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000132/0000059478-15-000132-index.htm.","url":"https://asof.is/claim/clm_8290EEB5A3E8","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,064,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8290EEB5A3E8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2015, filed 2015-04-30"}},{"date":"2015-03-31","until":"2015-06-30","published":"2015-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,039,300,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_F4A8EF5F8415, https://asof.is/claim/clm_F4A8EF5F8415, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000132/0000059478-15-000132-index.htm.","url":"https://asof.is/claim/clm_F4A8EF5F8415","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,039,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F4A8EF5F8415","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2015, filed 2015-04-30"}},{"date":"2015-04-20","until":"2015-07-20","published":"2015-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,109,741,140 shares\", as of 2015-04-20 (until 2015-07-20). Claim clm_CD315B6AC013, https://asof.is/claim/clm_CD315B6AC013, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000132/0000059478-15-000132-index.htm.","url":"https://asof.is/claim/clm_CD315B6AC013","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,109,741,140 shares","status":"superseded","assertable":true,"id":"clm_CD315B6AC013","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2015, filed 2015-04-30"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 14,670,300,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_05E3ACEFE9F4, https://asof.is/claim/clm_05E3ACEFE9F4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000164/0000059478-15-000164-index.htm.","url":"https://asof.is/claim/clm_05E3ACEFE9F4","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"14,670,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_05E3ACEFE9F4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2015, filed 2015-07-30"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 36,036,600,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_29CF1248110D, https://asof.is/claim/clm_29CF1248110D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000164/0000059478-15-000164-index.htm.","url":"https://asof.is/claim/clm_29CF1248110D","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"36,036,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_29CF1248110D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2015, filed 2015-07-30"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,315,500,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_37260443EDA4, https://asof.is/claim/clm_37260443EDA4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000164/0000059478-15-000164-index.htm.","url":"https://asof.is/claim/clm_37260443EDA4","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,315,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_37260443EDA4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2015, filed 2015-07-30"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,169,500,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_6CB072A7991A, https://asof.is/claim/clm_6CB072A7991A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000164/0000059478-15-000164-index.htm.","url":"https://asof.is/claim/clm_6CB072A7991A","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,169,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6CB072A7991A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2015, filed 2015-07-30"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 600,800,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_AA212525ACD8, https://asof.is/claim/clm_AA212525ACD8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000164/0000059478-15-000164-index.htm.","url":"https://asof.is/claim/clm_AA212525ACD8","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"600,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AA212525ACD8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2015, filed 2015-07-30"}},{"date":"2015-06-30","until":"2015-09-30","published":"2015-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 4,978,700,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_F15C91D955BE, https://asof.is/claim/clm_F15C91D955BE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000164/0000059478-15-000164-index.htm.","url":"https://asof.is/claim/clm_F15C91D955BE","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"4,978,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F15C91D955BE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2015, filed 2015-07-30"}},{"date":"2015-07-20","until":"2015-10-19","published":"2015-07-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,108,540,541 shares\", as of 2015-07-20 (until 2015-10-19). Claim clm_BE11DE44FF9B, https://asof.is/claim/clm_BE11DE44FF9B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000164/0000059478-15-000164-index.htm.","url":"https://asof.is/claim/clm_BE11DE44FF9B","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,108,540,541 shares","status":"superseded","assertable":true,"id":"clm_BE11DE44FF9B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2015, filed 2015-07-30"}},{"date":"2015-09-30","until":"2015-12-31","published":"2015-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 36,304,700,000 United States dollar\", as of 2015-09-30 (until 2015-12-31). Claim clm_2828BE832FA8, https://asof.is/claim/clm_2828BE832FA8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000175/0000059478-15-000175-index.htm.","url":"https://asof.is/claim/clm_2828BE832FA8","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"36,304,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2828BE832FA8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2015, filed 2015-10-30"}},{"date":"2015-09-30","until":"2016-03-31","published":"2015-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,143,400,000 United States dollar\", as of 2015-09-30 (until 2016-03-31). Claim clm_A0FDA0736382, https://asof.is/claim/clm_A0FDA0736382, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000175/0000059478-15-000175-index.htm.","url":"https://asof.is/claim/clm_A0FDA0736382","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,143,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A0FDA0736382","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2015, filed 2015-10-30"}},{"date":"2015-09-30","until":"2016-03-31","published":"2015-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 4,959,700,000 United States dollar\", as of 2015-09-30 (until 2016-03-31). Claim clm_AED191B23B0D, https://asof.is/claim/clm_AED191B23B0D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000175/0000059478-15-000175-index.htm.","url":"https://asof.is/claim/clm_AED191B23B0D","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"4,959,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AED191B23B0D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2015, filed 2015-10-30"}},{"date":"2015-09-30","until":"2016-03-31","published":"2015-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 799,700,000 United States dollar\", as of 2015-09-30 (until 2016-03-31). Claim clm_BA9581291E40, https://asof.is/claim/clm_BA9581291E40, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000175/0000059478-15-000175-index.htm.","url":"https://asof.is/claim/clm_BA9581291E40","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"799,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BA9581291E40","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2015, filed 2015-10-30"}},{"date":"2015-09-30","until":"2015-12-31","published":"2015-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,238,800,000 United States dollar\", as of 2015-09-30 (until 2015-12-31). Claim clm_C5B1D581A796, https://asof.is/claim/clm_C5B1D581A796, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000175/0000059478-15-000175-index.htm.","url":"https://asof.is/claim/clm_C5B1D581A796","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,238,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C5B1D581A796","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2015, filed 2015-10-30"}},{"date":"2015-09-30","until":"2015-12-31","published":"2015-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 15,221,400,000 United States dollar\", as of 2015-09-30 (until 2015-12-31). Claim clm_EECD80D1A6CE, https://asof.is/claim/clm_EECD80D1A6CE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000175/0000059478-15-000175-index.htm.","url":"https://asof.is/claim/clm_EECD80D1A6CE","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"15,221,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EECD80D1A6CE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2015, filed 2015-10-30"}},{"date":"2015-10-19","until":"2016-02-12","published":"2015-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,108,076,549 shares\", as of 2015-10-19 (until 2016-02-12). Claim clm_390A800B86E6, https://asof.is/claim/clm_390A800B86E6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947815000175/0000059478-15-000175-index.htm.","url":"https://asof.is/claim/clm_390A800B86E6","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,108,076,549 shares","status":"superseded","assertable":true,"id":"clm_390A800B86E6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2015, filed 2015-10-30"}},{"date":"2015-12-31","until":"2016-12-31","published":"2016-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company research and development: 4,796,400,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_1B276AE2739D, https://asof.is/claim/clm_1B276AE2739D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000321/0000059478-16-000321-index.htm.","url":"https://asof.is/claim/clm_1B276AE2739D","accessed":"2026-11-08"},"kind":"money","predicate":"research_and_development","value":"4,796,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1B276AE2739D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2015, filed 2016-02-19"}},{"date":"2015-12-31","until":"2016-03-31","published":"2016-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 35,568,900,000 United States dollar\", as of 2015-12-31 (until 2016-03-31). Claim clm_3FF278349F90, https://asof.is/claim/clm_3FF278349F90, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000321/0000059478-16-000321-index.htm.","url":"https://asof.is/claim/clm_3FF278349F90","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"35,568,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3FF278349F90","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2015, filed 2016-02-19"}},{"date":"2015-12-31","until":"2016-03-31","published":"2016-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 14,571,300,000 United States dollar\", as of 2015-12-31 (until 2016-03-31). Claim clm_49441DF34787, https://asof.is/claim/clm_49441DF34787, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000321/0000059478-16-000321-index.htm.","url":"https://asof.is/claim/clm_49441DF34787","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"14,571,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_49441DF34787","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2015, filed 2016-02-19"}},{"date":"2015-12-31","until":"2016-12-31","published":"2016-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company net income: 2,408,400,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_4EA9C0C3EB44, https://asof.is/claim/clm_4EA9C0C3EB44, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000321/0000059478-16-000321-index.htm.","url":"https://asof.is/claim/clm_4EA9C0C3EB44","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"2,408,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4EA9C0C3EB44","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2015, filed 2016-02-19"}},{"date":"2015-12-31","until":"2016-12-31","published":"2016-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company revenue: 19,958,700,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_53995054E4D5, https://asof.is/claim/clm_53995054E4D5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000321/0000059478-16-000321-index.htm.","url":"https://asof.is/claim/clm_53995054E4D5","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"19,958,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_53995054E4D5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2015, filed 2016-02-19"}},{"date":"2015-12-31","until":"2016-03-31","published":"2016-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,666,400,000 United States dollar\", as of 2015-12-31 (until 2016-03-31). Claim clm_87E254B2B673, https://asof.is/claim/clm_87E254B2B673, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000321/0000059478-16-000321-index.htm.","url":"https://asof.is/claim/clm_87E254B2B673","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,666,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_87E254B2B673","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2015, filed 2016-02-19"}},{"date":"2016-02-12","until":"2016-04-18","published":"2016-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,106,093,485 shares\", as of 2016-02-12 (until 2016-04-18). Claim clm_954C4C3D7EBE, https://asof.is/claim/clm_954C4C3D7EBE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000321/0000059478-16-000321-index.htm.","url":"https://asof.is/claim/clm_954C4C3D7EBE","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,106,093,485 shares","status":"superseded","assertable":true,"id":"clm_954C4C3D7EBE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2015, filed 2016-02-19"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,221,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_0515A159428D, https://asof.is/claim/clm_0515A159428D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000353/0000059478-16-000353-index.htm.","url":"https://asof.is/claim/clm_0515A159428D","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,221,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0515A159428D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2016, filed 2016-04-29"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 4,865,100,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_1F4EC3A3B4D5, https://asof.is/claim/clm_1F4EC3A3B4D5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000353/0000059478-16-000353-index.htm.","url":"https://asof.is/claim/clm_1F4EC3A3B4D5","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"4,865,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1F4EC3A3B4D5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2016, filed 2016-04-29"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 34,691,800,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_35074E027D38, https://asof.is/claim/clm_35074E027D38, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000353/0000059478-16-000353-index.htm.","url":"https://asof.is/claim/clm_35074E027D38","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"34,691,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_35074E027D38","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2016, filed 2016-04-29"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 15,009,900,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_98CA7C046AF8, https://asof.is/claim/clm_98CA7C046AF8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000353/0000059478-16-000353-index.htm.","url":"https://asof.is/claim/clm_98CA7C046AF8","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"15,009,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_98CA7C046AF8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2016, filed 2016-04-29"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 440,100,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_F4315B9F6A7A, https://asof.is/claim/clm_F4315B9F6A7A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000353/0000059478-16-000353-index.htm.","url":"https://asof.is/claim/clm_F4315B9F6A7A","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"440,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F4315B9F6A7A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2016, filed 2016-04-29"}},{"date":"2016-03-31","until":"2016-06-30","published":"2016-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 2,307,600,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_FA870C5AC561, https://asof.is/claim/clm_FA870C5AC561, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000353/0000059478-16-000353-index.htm.","url":"https://asof.is/claim/clm_FA870C5AC561","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,307,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FA870C5AC561","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2016, filed 2016-04-29"}},{"date":"2016-04-18","until":"2016-07-18","published":"2016-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,103,837,002 shares\", as of 2016-04-18 (until 2016-07-18). Claim clm_29E5B3F2C398, https://asof.is/claim/clm_29E5B3F2C398, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000353/0000059478-16-000353-index.htm.","url":"https://asof.is/claim/clm_29E5B3F2C398","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,103,837,002 shares","status":"superseded","assertable":true,"id":"clm_29E5B3F2C398","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2016, filed 2016-04-29"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 747,700,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_3D04484E2898, https://asof.is/claim/clm_3D04484E2898, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000399/0000059478-16-000399-index.htm.","url":"https://asof.is/claim/clm_3D04484E2898","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"747,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3D04484E2898","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2016, filed 2016-07-28"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,404,800,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_72B1497E5670, https://asof.is/claim/clm_72B1497E5670, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000399/0000059478-16-000399-index.htm.","url":"https://asof.is/claim/clm_72B1497E5670","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,404,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_72B1497E5670","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2016, filed 2016-07-28"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,238,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_AF8251DBBE60, https://asof.is/claim/clm_AF8251DBBE60, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000399/0000059478-16-000399-index.htm.","url":"https://asof.is/claim/clm_AF8251DBBE60","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,238,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AF8251DBBE60","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2016, filed 2016-07-28"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 36,475,300,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_C7DDD74DF355, https://asof.is/claim/clm_C7DDD74DF355, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000399/0000059478-16-000399-index.htm.","url":"https://asof.is/claim/clm_C7DDD74DF355","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"36,475,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C7DDD74DF355","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2016, filed 2016-07-28"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 14,637,300,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_C85B54CB3609, https://asof.is/claim/clm_C85B54CB3609, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000399/0000059478-16-000399-index.htm.","url":"https://asof.is/claim/clm_C85B54CB3609","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"14,637,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C85B54CB3609","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2016, filed 2016-07-28"}},{"date":"2016-06-30","until":"2016-09-30","published":"2016-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,335,900,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_E31AD6E2CA61, https://asof.is/claim/clm_E31AD6E2CA61, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000399/0000059478-16-000399-index.htm.","url":"https://asof.is/claim/clm_E31AD6E2CA61","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,335,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E31AD6E2CA61","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2016, filed 2016-07-28"}},{"date":"2016-07-18","until":"2016-10-17","published":"2016-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,103,843,444 shares\", as of 2016-07-18 (until 2016-10-17). Claim clm_0398CFEE2BD5, https://asof.is/claim/clm_0398CFEE2BD5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000399/0000059478-16-000399-index.htm.","url":"https://asof.is/claim/clm_0398CFEE2BD5","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,103,843,444 shares","status":"superseded","assertable":true,"id":"clm_0398CFEE2BD5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2016, filed 2016-07-28"}},{"date":"2016-09-30","until":"2017-03-31","published":"2016-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 778,000,000 United States dollar\", as of 2016-09-30 (until 2017-03-31). Claim clm_5525F074C916, https://asof.is/claim/clm_5525F074C916, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000440/0000059478-16-000440-index.htm.","url":"https://asof.is/claim/clm_5525F074C916","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"778,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5525F074C916","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2016, filed 2016-10-28"}},{"date":"2016-09-30","until":"2016-12-31","published":"2016-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 15,589,200,000 United States dollar\", as of 2016-09-30 (until 2016-12-31). Claim clm_7EE1B4067292, https://asof.is/claim/clm_7EE1B4067292, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000440/0000059478-16-000440-index.htm.","url":"https://asof.is/claim/clm_7EE1B4067292","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"15,589,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7EE1B4067292","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2016, filed 2016-10-28"}},{"date":"2016-09-30","until":"2016-12-31","published":"2016-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,489,000,000 United States dollar\", as of 2016-09-30 (until 2016-12-31). Claim clm_8A112E3D2238, https://asof.is/claim/clm_8A112E3D2238, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000440/0000059478-16-000440-index.htm.","url":"https://asof.is/claim/clm_8A112E3D2238","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,489,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8A112E3D2238","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2016, filed 2016-10-28"}},{"date":"2016-09-30","until":"2016-12-31","published":"2016-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 37,590,300,000 United States dollar\", as of 2016-09-30 (until 2016-12-31). Claim clm_A1847770D205, https://asof.is/claim/clm_A1847770D205, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000440/0000059478-16-000440-index.htm.","url":"https://asof.is/claim/clm_A1847770D205","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"37,590,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A1847770D205","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2016, filed 2016-10-28"}},{"date":"2016-09-30","until":"2017-03-31","published":"2016-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,236,400,000 United States dollar\", as of 2016-09-30 (until 2017-03-31). Claim clm_A8E893E76F87, https://asof.is/claim/clm_A8E893E76F87, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000440/0000059478-16-000440-index.htm.","url":"https://asof.is/claim/clm_A8E893E76F87","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,236,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A8E893E76F87","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2016, filed 2016-10-28"}},{"date":"2016-09-30","until":"2017-03-31","published":"2016-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,191,700,000 United States dollar\", as of 2016-09-30 (until 2017-03-31). Claim clm_ADD269D8EB64, https://asof.is/claim/clm_ADD269D8EB64, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000440/0000059478-16-000440-index.htm.","url":"https://asof.is/claim/clm_ADD269D8EB64","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,191,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_ADD269D8EB64","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2016, filed 2016-10-28"}},{"date":"2016-10-17","until":"2017-02-13","published":"2016-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,103,948,230 shares\", as of 2016-10-17 (until 2017-02-13). Claim clm_49EBF0007D5C, https://asof.is/claim/clm_49EBF0007D5C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947816000440/0000059478-16-000440-index.htm.","url":"https://asof.is/claim/clm_49EBF0007D5C","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,103,948,230 shares","status":"superseded","assertable":true,"id":"clm_49EBF0007D5C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2016, filed 2016-10-28"}},{"date":"2016-12-31","until":"2017-12-31","published":"2017-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company revenue: 21,222,100,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_09B0FB69C967, https://asof.is/claim/clm_09B0FB69C967, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000098/0000059478-17-000098-index.htm.","url":"https://asof.is/claim/clm_09B0FB69C967","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"21,222,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_09B0FB69C967","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2016, filed 2017-02-21"}},{"date":"2016-12-31","until":"2017-03-31","published":"2017-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 14,007,700,000 United States dollar\", as of 2016-12-31 (until 2017-03-31). Claim clm_0A273F2F1080, https://asof.is/claim/clm_0A273F2F1080, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000098/0000059478-17-000098-index.htm.","url":"https://asof.is/claim/clm_0A273F2F1080","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"14,007,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0A273F2F1080","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2016, filed 2017-02-21"}},{"date":"2016-12-31","until":"2017-12-31","published":"2017-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company research and development: 5,243,900,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_6D0F6FB5867B, https://asof.is/claim/clm_6D0F6FB5867B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000098/0000059478-17-000098-index.htm.","url":"https://asof.is/claim/clm_6D0F6FB5867B","accessed":"2026-11-08"},"kind":"money","predicate":"research_and_development","value":"5,243,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6D0F6FB5867B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2016, filed 2017-02-21"}},{"date":"2016-12-31","until":"2017-03-31","published":"2017-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 4,582,100,000 United States dollar\", as of 2016-12-31 (until 2017-03-31). Claim clm_97CE4D7A5431, https://asof.is/claim/clm_97CE4D7A5431, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000098/0000059478-17-000098-index.htm.","url":"https://asof.is/claim/clm_97CE4D7A5431","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"4,582,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_97CE4D7A5431","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2016, filed 2017-02-21"}},{"date":"2016-12-31","until":"2017-03-31","published":"2017-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 38,805,900,000 United States dollar\", as of 2016-12-31 (until 2017-03-31). Claim clm_DCAB670958F3, https://asof.is/claim/clm_DCAB670958F3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000098/0000059478-17-000098-index.htm.","url":"https://asof.is/claim/clm_DCAB670958F3","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"38,805,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DCAB670958F3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2016, filed 2017-02-21"}},{"date":"2016-12-31","until":"2017-12-31","published":"2017-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company net income: 2,737,600,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_ECD98570FDF4, https://asof.is/claim/clm_ECD98570FDF4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000098/0000059478-17-000098-index.htm.","url":"https://asof.is/claim/clm_ECD98570FDF4","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"2,737,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_ECD98570FDF4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2016, filed 2017-02-21"}},{"date":"2017-02-13","until":"2017-04-24","published":"2017-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,103,352,450 shares\", as of 2017-02-13 (until 2017-04-24). Claim clm_ABD29EC217BC, https://asof.is/claim/clm_ABD29EC217BC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000098/0000059478-17-000098-index.htm.","url":"https://asof.is/claim/clm_ABD29EC217BC","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,103,352,450 shares","status":"superseded","assertable":true,"id":"clm_ABD29EC217BC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2016, filed 2017-02-21"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,228,300,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_038044B3B9B8, https://asof.is/claim/clm_038044B3B9B8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000129/0000059478-17-000129-index.htm.","url":"https://asof.is/claim/clm_038044B3B9B8","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,228,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_038044B3B9B8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2017, filed 2017-05-01"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: -110,800,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_204BF56894A9, https://asof.is/claim/clm_204BF56894A9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000129/0000059478-17-000129-index.htm.","url":"https://asof.is/claim/clm_204BF56894A9","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"-110,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_204BF56894A9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2017, filed 2017-05-01"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 14,031,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_44091369BB0F, https://asof.is/claim/clm_44091369BB0F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000129/0000059478-17-000129-index.htm.","url":"https://asof.is/claim/clm_44091369BB0F","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"14,031,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_44091369BB0F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2017, filed 2017-05-01"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,238,300,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_B519477BC9FD, https://asof.is/claim/clm_B519477BC9FD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000129/0000059478-17-000129-index.htm.","url":"https://asof.is/claim/clm_B519477BC9FD","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,238,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B519477BC9FD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2017, filed 2017-05-01"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 2,616,900,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_BF2787D27F9E, https://asof.is/claim/clm_BF2787D27F9E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000129/0000059478-17-000129-index.htm.","url":"https://asof.is/claim/clm_BF2787D27F9E","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,616,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BF2787D27F9E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2017, filed 2017-05-01"}},{"date":"2017-03-31","until":"2017-06-30","published":"2017-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 37,624,300,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_EF50813461C3, https://asof.is/claim/clm_EF50813461C3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000129/0000059478-17-000129-index.htm.","url":"https://asof.is/claim/clm_EF50813461C3","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"37,624,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EF50813461C3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2017, filed 2017-05-01"}},{"date":"2017-04-24","until":"2017-07-17","published":"2017-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,103,388,743 shares\", as of 2017-04-24 (until 2017-07-17). Claim clm_4C12B1C9DF34, https://asof.is/claim/clm_4C12B1C9DF34, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000129/0000059478-17-000129-index.htm.","url":"https://asof.is/claim/clm_4C12B1C9DF34","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,103,388,743 shares","status":"superseded","assertable":true,"id":"clm_4C12B1C9DF34","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2017, filed 2017-05-01"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,008,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_04082787F8B3, https://asof.is/claim/clm_04082787F8B3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000183/0000059478-17-000183-index.htm.","url":"https://asof.is/claim/clm_04082787F8B3","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,008,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_04082787F8B3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2017, filed 2017-07-28"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,824,300,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_1D6AC1DB5DDA, https://asof.is/claim/clm_1D6AC1DB5DDA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000183/0000059478-17-000183-index.htm.","url":"https://asof.is/claim/clm_1D6AC1DB5DDA","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,824,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1D6AC1DB5DDA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2017, filed 2017-07-28"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,069,900,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_38F458D1BB00, https://asof.is/claim/clm_38F458D1BB00, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000183/0000059478-17-000183-index.htm.","url":"https://asof.is/claim/clm_38F458D1BB00","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,069,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_38F458D1BB00","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2017, filed 2017-07-28"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 14,100,800,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_3C0A3B01161E, https://asof.is/claim/clm_3C0A3B01161E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000183/0000059478-17-000183-index.htm.","url":"https://asof.is/claim/clm_3C0A3B01161E","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"14,100,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3C0A3B01161E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2017, filed 2017-07-28"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,250,900,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_930CA1B90992, https://asof.is/claim/clm_930CA1B90992, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000183/0000059478-17-000183-index.htm.","url":"https://asof.is/claim/clm_930CA1B90992","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,250,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_930CA1B90992","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2017, filed 2017-07-28"}},{"date":"2017-06-30","until":"2017-09-30","published":"2017-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 40,946,500,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_9BAE6ED0A697, https://asof.is/claim/clm_9BAE6ED0A697, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000183/0000059478-17-000183-index.htm.","url":"https://asof.is/claim/clm_9BAE6ED0A697","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"40,946,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9BAE6ED0A697","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2017, filed 2017-07-28"}},{"date":"2017-07-17","until":"2017-10-23","published":"2017-07-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,100,988,944 shares\", as of 2017-07-17 (until 2017-10-23). Claim clm_BB222876F045, https://asof.is/claim/clm_BB222876F045, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000183/0000059478-17-000183-index.htm.","url":"https://asof.is/claim/clm_BB222876F045","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,100,988,944 shares","status":"superseded","assertable":true,"id":"clm_BB222876F045","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2017, filed 2017-07-28"}},{"date":"2017-09-30","until":"2018-03-31","published":"2017-10-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,319,400,000 United States dollar\", as of 2017-09-30 (until 2018-03-31). Claim clm_4BBDB8977EFF, https://asof.is/claim/clm_4BBDB8977EFF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000204/0000059478-17-000204-index.htm.","url":"https://asof.is/claim/clm_4BBDB8977EFF","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,319,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4BBDB8977EFF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2017, filed 2017-10-27"}},{"date":"2017-09-30","until":"2018-03-31","published":"2017-10-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,658,000,000 United States dollar\", as of 2017-09-30 (until 2018-03-31). Claim clm_5FD91BF932E6, https://asof.is/claim/clm_5FD91BF932E6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000204/0000059478-17-000204-index.htm.","url":"https://asof.is/claim/clm_5FD91BF932E6","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,658,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5FD91BF932E6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2017, filed 2017-10-27"}},{"date":"2017-09-30","until":"2017-12-31","published":"2017-10-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 14,890,300,000 United States dollar\", as of 2017-09-30 (until 2017-12-31). Claim clm_6016D10EB1D9, https://asof.is/claim/clm_6016D10EB1D9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000204/0000059478-17-000204-index.htm.","url":"https://asof.is/claim/clm_6016D10EB1D9","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"14,890,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6016D10EB1D9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2017, filed 2017-10-27"}},{"date":"2017-09-30","until":"2017-12-31","published":"2017-10-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,724,300,000 United States dollar\", as of 2017-09-30 (until 2017-12-31). Claim clm_7B8BDD309F9A, https://asof.is/claim/clm_7B8BDD309F9A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000204/0000059478-17-000204-index.htm.","url":"https://asof.is/claim/clm_7B8BDD309F9A","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,724,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7B8BDD309F9A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2017, filed 2017-10-27"}},{"date":"2017-09-30","until":"2017-12-31","published":"2017-10-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 43,010,400,000 United States dollar\", as of 2017-09-30 (until 2017-12-31). Claim clm_C299504341FF, https://asof.is/claim/clm_C299504341FF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000204/0000059478-17-000204-index.htm.","url":"https://asof.is/claim/clm_C299504341FF","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"43,010,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C299504341FF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2017, filed 2017-10-27"}},{"date":"2017-09-30","until":"2018-03-31","published":"2017-10-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 555,600,000 United States dollar\", as of 2017-09-30 (until 2018-03-31). Claim clm_F933C58020E5, https://asof.is/claim/clm_F933C58020E5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000204/0000059478-17-000204-index.htm.","url":"https://asof.is/claim/clm_F933C58020E5","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"555,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F933C58020E5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2017, filed 2017-10-27"}},{"date":"2017-10-23","until":"2018-02-14","published":"2017-10-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,101,094,711 shares\", as of 2017-10-23 (until 2018-02-14). Claim clm_D59D78AA6954, https://asof.is/claim/clm_D59D78AA6954, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947817000204/0000059478-17-000204-index.htm.","url":"https://asof.is/claim/clm_D59D78AA6954","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,101,094,711 shares","status":"superseded","assertable":true,"id":"clm_D59D78AA6954","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2017, filed 2017-10-27"}},{"date":"2017-12-31","until":"2018-12-31","published":"2018-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company revenue: 22,871,300,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_0C495BD0FBE4, https://asof.is/claim/clm_0C495BD0FBE4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000089/0000059478-18-000089-index.htm.","url":"https://asof.is/claim/clm_0C495BD0FBE4","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"22,871,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0C495BD0FBE4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2017, filed 2018-02-20"}},{"date":"2017-12-31","until":"2018-12-31","published":"2018-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company research and development: 5,281,800,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_1D6D085414BC, https://asof.is/claim/clm_1D6D085414BC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000089/0000059478-18-000089-index.htm.","url":"https://asof.is/claim/clm_1D6D085414BC","accessed":"2026-11-08"},"kind":"money","predicate":"research_and_development","value":"5,281,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1D6D085414BC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2017, filed 2018-02-20"}},{"date":"2017-12-31","until":"2018-03-31","published":"2018-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 6,536,200,000 United States dollar\", as of 2017-12-31 (until 2018-03-31). Claim clm_7B8D449B4862, https://asof.is/claim/clm_7B8D449B4862, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000089/0000059478-18-000089-index.htm.","url":"https://asof.is/claim/clm_7B8D449B4862","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"6,536,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7B8D449B4862","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2017, filed 2018-02-20"}},{"date":"2017-12-31","until":"2018-03-31","published":"2018-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 44,981,000,000 United States dollar\", as of 2017-12-31 (until 2018-03-31). Claim clm_9463DD58F180, https://asof.is/claim/clm_9463DD58F180, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000089/0000059478-18-000089-index.htm.","url":"https://asof.is/claim/clm_9463DD58F180","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"44,981,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9463DD58F180","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2017, filed 2018-02-20"}},{"date":"2017-12-31","until":"2018-12-31","published":"2018-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company net income: -204,100,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_A49582D43487, https://asof.is/claim/clm_A49582D43487, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000089/0000059478-18-000089-index.htm.","url":"https://asof.is/claim/clm_A49582D43487","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"-204,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A49582D43487","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2017, filed 2018-02-20"}},{"date":"2017-12-31","until":"2018-03-31","published":"2018-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 11,592,200,000 United States dollar\", as of 2017-12-31 (until 2018-03-31). Claim clm_C9D7EC5AA793, https://asof.is/claim/clm_C9D7EC5AA793, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000089/0000059478-18-000089-index.htm.","url":"https://asof.is/claim/clm_C9D7EC5AA793","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"11,592,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C9D7EC5AA793","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2017, filed 2018-02-20"}},{"date":"2018-02-14","until":"2018-04-23","published":"2018-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,095,597,580 shares\", as of 2018-02-14 (until 2018-04-23). Claim clm_89BF6F9A0371, https://asof.is/claim/clm_89BF6F9A0371, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000089/0000059478-18-000089-index.htm.","url":"https://asof.is/claim/clm_89BF6F9A0371","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,095,597,580 shares","status":"superseded","assertable":true,"id":"clm_89BF6F9A0371","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2017, filed 2018-02-20"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 44,355,600,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_03A59D1CFECD, https://asof.is/claim/clm_03A59D1CFECD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000136/0000059478-18-000136-index.htm.","url":"https://asof.is/claim/clm_03A59D1CFECD","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"44,355,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_03A59D1CFECD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2018, filed 2018-04-27"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 14,527,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_1F8EC1251DE2, https://asof.is/claim/clm_1F8EC1251DE2, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000136/0000059478-18-000136-index.htm.","url":"https://asof.is/claim/clm_1F8EC1251DE2","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"14,527,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1F8EC1251DE2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2018, filed 2018-04-27"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,700,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_2064AA6387A6, https://asof.is/claim/clm_2064AA6387A6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000136/0000059478-18-000136-index.htm.","url":"https://asof.is/claim/clm_2064AA6387A6","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,700,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2064AA6387A6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2018, filed 2018-04-27"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,176,900,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_5F2AD88EFADC, https://asof.is/claim/clm_5F2AD88EFADC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000136/0000059478-18-000136-index.htm.","url":"https://asof.is/claim/clm_5F2AD88EFADC","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,176,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5F2AD88EFADC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2018, filed 2018-04-27"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,217,400,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_D7E9283EA9D1, https://asof.is/claim/clm_D7E9283EA9D1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000136/0000059478-18-000136-index.htm.","url":"https://asof.is/claim/clm_D7E9283EA9D1","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,217,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D7E9283EA9D1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2018, filed 2018-04-27"}},{"date":"2018-03-31","until":"2018-06-30","published":"2018-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,084,300,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_F28DDDE756C5, https://asof.is/claim/clm_F28DDDE756C5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000136/0000059478-18-000136-index.htm.","url":"https://asof.is/claim/clm_F28DDDE756C5","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,084,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F28DDDE756C5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2018, filed 2018-04-27"}},{"date":"2018-04-23","until":"2018-07-23","published":"2018-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,085,430,420 shares\", as of 2018-04-23 (until 2018-07-23). Claim clm_ECF7FEC12945, https://asof.is/claim/clm_ECF7FEC12945, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000136/0000059478-18-000136-index.htm.","url":"https://asof.is/claim/clm_ECF7FEC12945","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,085,430,420 shares","status":"superseded","assertable":true,"id":"clm_ECF7FEC12945","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2018, filed 2018-04-27"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-07-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: -259,900,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_38DEDDCE8663, https://asof.is/claim/clm_38DEDDCE8663, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000188/0000059478-18-000188-index.htm.","url":"https://asof.is/claim/clm_38DEDDCE8663","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"-259,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_38DEDDCE8663","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2018, filed 2018-07-25"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-07-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 6,817,300,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_AF6D10B3DE1F, https://asof.is/claim/clm_AF6D10B3DE1F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000188/0000059478-18-000188-index.htm.","url":"https://asof.is/claim/clm_AF6D10B3DE1F","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"6,817,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AF6D10B3DE1F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2018, filed 2018-07-25"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-07-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,333,100,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_B3200D4A3CEB, https://asof.is/claim/clm_B3200D4A3CEB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000188/0000059478-18-000188-index.htm.","url":"https://asof.is/claim/clm_B3200D4A3CEB","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,333,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B3200D4A3CEB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2018, filed 2018-07-25"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-07-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 42,359,200,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_D6B2544E9EB7, https://asof.is/claim/clm_D6B2544E9EB7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000188/0000059478-18-000188-index.htm.","url":"https://asof.is/claim/clm_D6B2544E9EB7","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"42,359,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D6B2544E9EB7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2018, filed 2018-07-25"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-07-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 11,555,200,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_E89D6F88DF2A, https://asof.is/claim/clm_E89D6F88DF2A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000188/0000059478-18-000188-index.htm.","url":"https://asof.is/claim/clm_E89D6F88DF2A","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"11,555,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E89D6F88DF2A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2018, filed 2018-07-25"}},{"date":"2018-06-30","until":"2018-09-30","published":"2018-07-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 6,355,200,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_F2315229046E, https://asof.is/claim/clm_F2315229046E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000188/0000059478-18-000188-index.htm.","url":"https://asof.is/claim/clm_F2315229046E","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"6,355,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F2315229046E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2018, filed 2018-07-25"}},{"date":"2018-07-23","until":"2018-11-02","published":"2018-07-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,073,987,856 shares\", as of 2018-07-23 (until 2018-11-02). Claim clm_B41B2FCF04EB, https://asof.is/claim/clm_B41B2FCF04EB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000188/0000059478-18-000188-index.htm.","url":"https://asof.is/claim/clm_B41B2FCF04EB","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,073,987,856 shares","status":"superseded","assertable":true,"id":"clm_B41B2FCF04EB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2018, filed 2018-07-25"}},{"date":"2018-09-30","until":"2018-12-31","published":"2018-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 13,076,600,000 United States dollar\", as of 2018-09-30 (until 2018-12-31). Claim clm_0EDBC9C09148, https://asof.is/claim/clm_0EDBC9C09148, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000256/0000059478-18-000256-index.htm.","url":"https://asof.is/claim/clm_0EDBC9C09148","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"13,076,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0EDBC9C09148","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2018, filed 2018-11-06"}},{"date":"2018-09-30","until":"2018-12-31","published":"2018-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 44,625,100,000 United States dollar\", as of 2018-09-30 (until 2018-12-31). Claim clm_7683EC843B20, https://asof.is/claim/clm_7683EC843B20, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000256/0000059478-18-000256-index.htm.","url":"https://asof.is/claim/clm_7683EC843B20","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"44,625,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7683EC843B20","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2018, filed 2018-11-06"}},{"date":"2018-09-30","until":"2019-03-31","published":"2018-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,149,500,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_A0296B1474AD, https://asof.is/claim/clm_A0296B1474AD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000256/0000059478-18-000256-index.htm.","url":"https://asof.is/claim/clm_A0296B1474AD","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,149,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A0296B1474AD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2018, filed 2018-11-06"}},{"date":"2018-09-30","until":"2018-12-31","published":"2018-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 8,960,000,000 United States dollar\", as of 2018-09-30 (until 2018-12-31). Claim clm_C653C5087E4A, https://asof.is/claim/clm_C653C5087E4A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000256/0000059478-18-000256-index.htm.","url":"https://asof.is/claim/clm_C653C5087E4A","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"8,960,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C653C5087E4A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2018, filed 2018-11-06"}},{"date":"2018-09-30","until":"2019-03-31","published":"2018-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,343,300,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_ED58AC0EB4EB, https://asof.is/claim/clm_ED58AC0EB4EB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000256/0000059478-18-000256-index.htm.","url":"https://asof.is/claim/clm_ED58AC0EB4EB","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,343,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_ED58AC0EB4EB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2018, filed 2018-11-06"}},{"date":"2018-09-30","until":"2019-03-31","published":"2018-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 6,061,900,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_FE144E331568, https://asof.is/claim/clm_FE144E331568, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000256/0000059478-18-000256-index.htm.","url":"https://asof.is/claim/clm_FE144E331568","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"6,061,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FE144E331568","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2018, filed 2018-11-06"}},{"date":"2018-11-02","until":"2019-02-13","published":"2018-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,059,322,255 shares\", as of 2018-11-02 (until 2019-02-13). Claim clm_7D2CCF7691F5, https://asof.is/claim/clm_7D2CCF7691F5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947818000256/0000059478-18-000256-index.htm.","url":"https://asof.is/claim/clm_7D2CCF7691F5","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,059,322,255 shares","status":"superseded","assertable":true,"id":"clm_7D2CCF7691F5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2018, filed 2018-11-06"}},{"date":"2018-12-31","until":"2019-12-31","published":"2019-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company research and development: 5,307,100,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_8C3635AEC49A, https://asof.is/claim/clm_8C3635AEC49A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000082/0000059478-19-000082-index.htm.","url":"https://asof.is/claim/clm_8C3635AEC49A","accessed":"2026-11-08"},"kind":"money","predicate":"research_and_development","value":"5,307,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8C3635AEC49A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2018, filed 2019-02-19"}},{"date":"2018-12-31","until":"2019-03-31","published":"2019-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 9,828,700,000 United States dollar\", as of 2018-12-31 (until 2019-03-31). Claim clm_9BB988E6330F, https://asof.is/claim/clm_9BB988E6330F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000082/0000059478-19-000082-index.htm.","url":"https://asof.is/claim/clm_9BB988E6330F","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"9,828,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9BB988E6330F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2018, filed 2019-02-19"}},{"date":"2018-12-31","until":"2019-12-31","published":"2019-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company net income: 3,232,000,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_B5442530014B, https://asof.is/claim/clm_B5442530014B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000082/0000059478-19-000082-index.htm.","url":"https://asof.is/claim/clm_B5442530014B","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"3,232,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B5442530014B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2018, filed 2019-02-19"}},{"date":"2018-12-31","until":"2019-03-31","published":"2019-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 7,998,200,000 United States dollar\", as of 2018-12-31 (until 2019-03-31). Claim clm_C02D22EACC34, https://asof.is/claim/clm_C02D22EACC34, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000082/0000059478-19-000082-index.htm.","url":"https://asof.is/claim/clm_C02D22EACC34","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"7,998,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C02D22EACC34","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2018, filed 2019-02-19"}},{"date":"2018-12-31","until":"2019-12-31","published":"2019-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company revenue: 24,555,700,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_E02BDD0A70F8, https://asof.is/claim/clm_E02BDD0A70F8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000082/0000059478-19-000082-index.htm.","url":"https://asof.is/claim/clm_E02BDD0A70F8","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"24,555,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E02BDD0A70F8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2018, filed 2019-02-19"}},{"date":"2018-12-31","until":"2019-03-31","published":"2019-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 43,908,400,000 United States dollar\", as of 2018-12-31 (until 2019-03-31). Claim clm_EEDFD1337A30, https://asof.is/claim/clm_EEDFD1337A30, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000082/0000059478-19-000082-index.htm.","url":"https://asof.is/claim/clm_EEDFD1337A30","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"43,908,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EEDFD1337A30","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2018, filed 2019-02-19"}},{"date":"2019-02-13","until":"2019-04-29","published":"2019-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 1,035,418,562 shares\", as of 2019-02-13 (until 2019-04-29). Claim clm_6F1E0522B9D9, https://asof.is/claim/clm_6F1E0522B9D9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000082/0000059478-19-000082-index.htm.","url":"https://asof.is/claim/clm_6F1E0522B9D9","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"1,035,418,562 shares","status":"superseded","assertable":true,"id":"clm_6F1E0522B9D9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2018, filed 2019-02-19"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 2,036,400,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_30B8DAA128A6, https://asof.is/claim/clm_30B8DAA128A6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000174/0000059478-19-000174-index.htm.","url":"https://asof.is/claim/clm_30B8DAA128A6","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,036,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_30B8DAA128A6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2019, filed 2019-05-02"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,230,500,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_48750F1D1FE6, https://asof.is/claim/clm_48750F1D1FE6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000174/0000059478-19-000174-index.htm.","url":"https://asof.is/claim/clm_48750F1D1FE6","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,230,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_48750F1D1FE6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2019, filed 2019-05-02"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,092,200,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_596A387D969F, https://asof.is/claim/clm_596A387D969F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000174/0000059478-19-000174-index.htm.","url":"https://asof.is/claim/clm_596A387D969F","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,092,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_596A387D969F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2019, filed 2019-05-02"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 38,006,800,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_95CD25DDBCB9, https://asof.is/claim/clm_95CD25DDBCB9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000174/0000059478-19-000174-index.htm.","url":"https://asof.is/claim/clm_95CD25DDBCB9","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"38,006,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_95CD25DDBCB9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2019, filed 2019-05-02"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 2,480,300,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_AC0198A66E27, https://asof.is/claim/clm_AC0198A66E27, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000174/0000059478-19-000174-index.htm.","url":"https://asof.is/claim/clm_AC0198A66E27","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"2,480,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AC0198A66E27","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2019, filed 2019-05-02"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 4,241,600,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_E7362E1D5592, https://asof.is/claim/clm_E7362E1D5592, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000174/0000059478-19-000174-index.htm.","url":"https://asof.is/claim/clm_E7362E1D5592","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"4,241,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E7362E1D5592","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2019, filed 2019-05-02"}},{"date":"2019-04-29","until":"2019-07-29","published":"2019-05-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 970,830,868 shares\", as of 2019-04-29 (until 2019-07-29). Claim clm_04D4986A2A84, https://asof.is/claim/clm_04D4986A2A84, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000174/0000059478-19-000174-index.htm.","url":"https://asof.is/claim/clm_04D4986A2A84","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"970,830,868 shares","status":"superseded","assertable":true,"id":"clm_04D4986A2A84","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2019, filed 2019-05-02"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,327,200,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_5FAB4A169B5B, https://asof.is/claim/clm_5FAB4A169B5B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000232/0000059478-19-000232-index.htm.","url":"https://asof.is/claim/clm_5FAB4A169B5B","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,327,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5FAB4A169B5B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2019, filed 2019-08-02"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 38,666,400,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_773D2FAE99CC, https://asof.is/claim/clm_773D2FAE99CC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000232/0000059478-19-000232-index.htm.","url":"https://asof.is/claim/clm_773D2FAE99CC","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"38,666,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_773D2FAE99CC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2019, filed 2019-08-02"}},{"date":"2019-06-30","until":"2019-12-31","published":"2019-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 2,290,200,000 United States dollar\", as of 2019-06-30 (until 2019-12-31). Claim clm_C88149C9C065, https://asof.is/claim/clm_C88149C9C065, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000232/0000059478-19-000232-index.htm.","url":"https://asof.is/claim/clm_C88149C9C065","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,290,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C88149C9C065","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2019, filed 2019-08-02"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,402,200,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_E28EAAD1FF5D, https://asof.is/claim/clm_E28EAAD1FF5D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000232/0000059478-19-000232-index.htm.","url":"https://asof.is/claim/clm_E28EAAD1FF5D","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,402,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E28EAAD1FF5D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2019, filed 2019-08-02"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 2,780,500,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_E2C19C62764F, https://asof.is/claim/clm_E2C19C62764F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000232/0000059478-19-000232-index.htm.","url":"https://asof.is/claim/clm_E2C19C62764F","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"2,780,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E2C19C62764F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2019, filed 2019-08-02"}},{"date":"2019-06-30","until":"2019-09-30","published":"2019-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,636,700,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_F113B6E2585B, https://asof.is/claim/clm_F113B6E2585B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000232/0000059478-19-000232-index.htm.","url":"https://asof.is/claim/clm_F113B6E2585B","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,636,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F113B6E2585B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2019, filed 2019-08-02"}},{"date":"2019-07-29","until":"2019-10-21","published":"2019-08-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 965,432,952 shares\", as of 2019-07-29 (until 2019-10-21). Claim clm_F82C28C9CB3F, https://asof.is/claim/clm_F82C28C9CB3F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000232/0000059478-19-000232-index.htm.","url":"https://asof.is/claim/clm_F82C28C9CB3F","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"965,432,952 shares","status":"superseded","assertable":true,"id":"clm_F82C28C9CB3F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2019, filed 2019-08-02"}},{"date":"2019-09-30","until":"2019-12-31","published":"2019-10-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 37,893,100,000 United States dollar\", as of 2019-09-30 (until 2019-12-31). Claim clm_519C86CA3C31, https://asof.is/claim/clm_519C86CA3C31, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000278/0000059478-19-000278-index.htm.","url":"https://asof.is/claim/clm_519C86CA3C31","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"37,893,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_519C86CA3C31","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2019, filed 2019-10-25"}},{"date":"2019-09-30","until":"2020-03-31","published":"2019-10-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,476,600,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_645E82FC1A32, https://asof.is/claim/clm_645E82FC1A32, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000278/0000059478-19-000278-index.htm.","url":"https://asof.is/claim/clm_645E82FC1A32","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,476,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_645E82FC1A32","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2019, filed 2019-10-25"}},{"date":"2019-09-30","until":"2020-03-31","published":"2019-10-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,380,900,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_DB9205986489, https://asof.is/claim/clm_DB9205986489, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000278/0000059478-19-000278-index.htm.","url":"https://asof.is/claim/clm_DB9205986489","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,380,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DB9205986489","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2019, filed 2019-10-25"}},{"date":"2019-09-30","until":"2019-12-31","published":"2019-10-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 3,382,500,000 United States dollar\", as of 2019-09-30 (until 2019-12-31). Claim clm_DC02ACC7A380, https://asof.is/claim/clm_DC02ACC7A380, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000278/0000059478-19-000278-index.htm.","url":"https://asof.is/claim/clm_DC02ACC7A380","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"3,382,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DC02ACC7A380","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2019, filed 2019-10-25"}},{"date":"2019-09-30","until":"2020-03-31","published":"2019-10-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,253,900,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_EF1A7976A06B, https://asof.is/claim/clm_EF1A7976A06B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000278/0000059478-19-000278-index.htm.","url":"https://asof.is/claim/clm_EF1A7976A06B","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,253,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EF1A7976A06B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2019, filed 2019-10-25"}},{"date":"2019-10-21","until":"2020-02-13","published":"2019-10-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 960,130,771 shares\", as of 2019-10-21 (until 2020-02-13). Claim clm_47134DBD0A87, https://asof.is/claim/clm_47134DBD0A87, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947819000278/0000059478-19-000278-index.htm.","url":"https://asof.is/claim/clm_47134DBD0A87","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"960,130,771 shares","status":"superseded","assertable":true,"id":"clm_47134DBD0A87","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2019, filed 2019-10-25"}},{"date":"2019-10-25","until":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company registrant name: ELI LILLY & Co\", as of 2019-10-25. Claim clm_95F26A6CA639, https://asof.is/claim/clm_95F26A6CA639, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000059478.","url":"https://asof.is/claim/clm_95F26A6CA639","accessed":"2026-11-08"},"kind":"other","predicate":"registrant_name","value":"ELI LILLY & Co","status":"valid","assertable":true,"id":"clm_95F26A6CA639","evidence":{"by":"sec-filing","on":"2026-11-08"}},{"date":"2019-12-31","until":"2020-03-31","published":"2020-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 2,337,500,000 United States dollar\", as of 2019-12-31 (until 2020-03-31). Claim clm_05C328F5524B, https://asof.is/claim/clm_05C328F5524B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/0000059478-20-000057-index.htm.","url":"https://asof.is/claim/clm_05C328F5524B","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,337,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_05C328F5524B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2019, filed 2020-02-19"}},{"date":"2019-12-31","until":"2020-03-31","published":"2020-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 39,286,100,000 United States dollar\", as of 2019-12-31 (until 2020-03-31). Claim clm_38B67E18082B, https://asof.is/claim/clm_38B67E18082B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/0000059478-20-000057-index.htm.","url":"https://asof.is/claim/clm_38B67E18082B","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"39,286,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_38B67E18082B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2019, filed 2020-02-19"}},{"date":"2019-12-31","until":"2020-12-31","published":"2020-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company research and development: 5,595,000,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_7AE5F777CC93, https://asof.is/claim/clm_7AE5F777CC93, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/0000059478-20-000057-index.htm.","url":"https://asof.is/claim/clm_7AE5F777CC93","accessed":"2026-11-08"},"kind":"money","predicate":"research_and_development","value":"5,595,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7AE5F777CC93","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2019, filed 2020-02-19"}},{"date":"2019-12-31","until":"2020-12-31","published":"2020-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company net income: 8,318,400,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_9519CD02B8A4, https://asof.is/claim/clm_9519CD02B8A4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/0000059478-20-000057-index.htm.","url":"https://asof.is/claim/clm_9519CD02B8A4","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"8,318,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9519CD02B8A4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2019, filed 2020-02-19"}},{"date":"2019-12-31","until":"2020-12-31","published":"2020-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company revenue: 22,319,500,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_BF0371526002, https://asof.is/claim/clm_BF0371526002, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/0000059478-20-000057-index.htm.","url":"https://asof.is/claim/clm_BF0371526002","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"22,319,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BF0371526002","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2019, filed 2020-02-19"}},{"date":"2019-12-31","until":"2020-03-31","published":"2020-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 2,606,900,000 United States dollar\", as of 2019-12-31 (until 2020-03-31). Claim clm_FFAE8DCE11A7, https://asof.is/claim/clm_FFAE8DCE11A7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/0000059478-20-000057-index.htm.","url":"https://asof.is/claim/clm_FFAE8DCE11A7","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"2,606,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FFAE8DCE11A7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2019, filed 2020-02-19"}},{"date":"2020-02-13","until":"2020-04-27","published":"2020-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 956,382,203 shares\", as of 2020-02-13 (until 2020-04-27). Claim clm_0CD54F69E65C, https://asof.is/claim/clm_0CD54F69E65C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000057/0000059478-20-000057-index.htm.","url":"https://asof.is/claim/clm_0CD54F69E65C","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"956,382,203 shares","status":"superseded","assertable":true,"id":"clm_0CD54F69E65C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2019, filed 2020-02-19"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 3,078,800,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_1D5999B4B912, https://asof.is/claim/clm_1D5999B4B912, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000104/0000059478-20-000104-index.htm.","url":"https://asof.is/claim/clm_1D5999B4B912","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"3,078,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1D5999B4B912","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2020, filed 2020-05-01"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 41,102,800,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_39C5B8921781, https://asof.is/claim/clm_39C5B8921781, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000104/0000059478-20-000104-index.htm.","url":"https://asof.is/claim/clm_39C5B8921781","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"41,102,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_39C5B8921781","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2020, filed 2020-05-01"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 1,699,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_6025AF0F4A10, https://asof.is/claim/clm_6025AF0F4A10, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000104/0000059478-20-000104-index.htm.","url":"https://asof.is/claim/clm_6025AF0F4A10","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"1,699,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6025AF0F4A10","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2020, filed 2020-05-01"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,456,500,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_636432A1644B, https://asof.is/claim/clm_636432A1644B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000104/0000059478-20-000104-index.htm.","url":"https://asof.is/claim/clm_636432A1644B","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,456,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_636432A1644B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2020, filed 2020-05-01"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,859,800,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_C179CB065205, https://asof.is/claim/clm_C179CB065205, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000104/0000059478-20-000104-index.htm.","url":"https://asof.is/claim/clm_C179CB065205","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,859,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C179CB065205","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2020, filed 2020-05-01"}},{"date":"2020-03-31","until":"2020-06-30","published":"2020-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,392,100,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_F9B6B8A2E8ED, https://asof.is/claim/clm_F9B6B8A2E8ED, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000104/0000059478-20-000104-index.htm.","url":"https://asof.is/claim/clm_F9B6B8A2E8ED","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,392,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F9B6B8A2E8ED","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2020, filed 2020-05-01"}},{"date":"2020-04-27","until":"2020-07-27","published":"2020-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 956,450,448 shares\", as of 2020-04-27 (until 2020-07-27). Claim clm_B27173165D21, https://asof.is/claim/clm_B27173165D21, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000104/0000059478-20-000104-index.htm.","url":"https://asof.is/claim/clm_B27173165D21","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"956,450,448 shares","status":"superseded","assertable":true,"id":"clm_B27173165D21","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2020, filed 2020-05-01"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,390,200,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_312F73F4FAFA, https://asof.is/claim/clm_312F73F4FAFA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000131/0000059478-20-000131-index.htm.","url":"https://asof.is/claim/clm_312F73F4FAFA","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,390,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_312F73F4FAFA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2020, filed 2020-07-31"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,412,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_65D146DB6B91, https://asof.is/claim/clm_65D146DB6B91, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000131/0000059478-20-000131-index.htm.","url":"https://asof.is/claim/clm_65D146DB6B91","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,412,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_65D146DB6B91","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2020, filed 2020-07-31"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 2,365,100,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_6814B9D207EB, https://asof.is/claim/clm_6814B9D207EB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000131/0000059478-20-000131-index.htm.","url":"https://asof.is/claim/clm_6814B9D207EB","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,365,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6814B9D207EB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2020, filed 2020-07-31"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 4,092,900,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_7235BBA18F5A, https://asof.is/claim/clm_7235BBA18F5A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000131/0000059478-20-000131-index.htm.","url":"https://asof.is/claim/clm_7235BBA18F5A","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"4,092,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7235BBA18F5A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2020, filed 2020-07-31"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 41,967,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_A901351CCECE, https://asof.is/claim/clm_A901351CCECE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000131/0000059478-20-000131-index.htm.","url":"https://asof.is/claim/clm_A901351CCECE","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"41,967,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A901351CCECE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2020, filed 2020-07-31"}},{"date":"2020-06-30","until":"2020-09-30","published":"2020-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,499,400,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_DFC5FB76B4A1, https://asof.is/claim/clm_DFC5FB76B4A1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000131/0000059478-20-000131-index.htm.","url":"https://asof.is/claim/clm_DFC5FB76B4A1","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,499,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DFC5FB76B4A1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2020, filed 2020-07-31"}},{"date":"2020-07-27","until":"2020-10-26","published":"2020-07-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 956,470,372 shares\", as of 2020-07-27 (until 2020-10-26). Claim clm_D0B36FB2290C, https://asof.is/claim/clm_D0B36FB2290C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000131/0000059478-20-000131-index.htm.","url":"https://asof.is/claim/clm_D0B36FB2290C","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"956,470,372 shares","status":"superseded","assertable":true,"id":"clm_D0B36FB2290C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2020, filed 2020-07-31"}},{"date":"2020-09-30","until":"2021-03-31","published":"2020-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,208,400,000 United States dollar\", as of 2020-09-30 (until 2021-03-31). Claim clm_332D40D8A3BD, https://asof.is/claim/clm_332D40D8A3BD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000155/0000059478-20-000155-index.htm.","url":"https://asof.is/claim/clm_332D40D8A3BD","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,208,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_332D40D8A3BD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2020, filed 2020-10-28"}},{"date":"2020-09-30","until":"2021-03-31","published":"2020-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,465,400,000 United States dollar\", as of 2020-09-30 (until 2021-03-31). Claim clm_3C4DC205EF64, https://asof.is/claim/clm_3C4DC205EF64, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000155/0000059478-20-000155-index.htm.","url":"https://asof.is/claim/clm_3C4DC205EF64","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,465,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3C4DC205EF64","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2020, filed 2020-10-28"}},{"date":"2020-09-30","until":"2020-12-31","published":"2020-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,595,300,000 United States dollar\", as of 2020-09-30 (until 2020-12-31). Claim clm_5345DC3B57B2, https://asof.is/claim/clm_5345DC3B57B2, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000155/0000059478-20-000155-index.htm.","url":"https://asof.is/claim/clm_5345DC3B57B2","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,595,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5345DC3B57B2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2020, filed 2020-10-28"}},{"date":"2020-09-30","until":"2021-03-31","published":"2020-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 5,740,600,000 United States dollar\", as of 2020-09-30 (until 2021-03-31). Claim clm_66B1C3D114E4, https://asof.is/claim/clm_66B1C3D114E4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000155/0000059478-20-000155-index.htm.","url":"https://asof.is/claim/clm_66B1C3D114E4","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"5,740,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_66B1C3D114E4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2020, filed 2020-10-28"}},{"date":"2020-09-30","until":"2020-12-31","published":"2020-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 4,826,900,000 United States dollar\", as of 2020-09-30 (until 2020-12-31). Claim clm_C8E43F07ABC7, https://asof.is/claim/clm_C8E43F07ABC7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000155/0000059478-20-000155-index.htm.","url":"https://asof.is/claim/clm_C8E43F07ABC7","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"4,826,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C8E43F07ABC7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2020, filed 2020-10-28"}},{"date":"2020-09-30","until":"2020-12-31","published":"2020-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 43,946,000,000 United States dollar\", as of 2020-09-30 (until 2020-12-31). Claim clm_D92638D7C314, https://asof.is/claim/clm_D92638D7C314, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000155/0000059478-20-000155-index.htm.","url":"https://asof.is/claim/clm_D92638D7C314","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"43,946,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D92638D7C314","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2020, filed 2020-10-28"}},{"date":"2020-10-26","until":"2021-02-12","published":"2020-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 956,581,598 shares\", as of 2020-10-26 (until 2021-02-12). Claim clm_8106333AD9A0, https://asof.is/claim/clm_8106333AD9A0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947820000155/0000059478-20-000155-index.htm.","url":"https://asof.is/claim/clm_8106333AD9A0","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"956,581,598 shares","status":"superseded","assertable":true,"id":"clm_8106333AD9A0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2020, filed 2020-10-28"}},{"date":"2020-12-31","until":"2021-12-31","published":"2021-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company research and development: 6,085,700,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_45941C7F343F, https://asof.is/claim/clm_45941C7F343F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000083/0000059478-21-000083-index.htm.","url":"https://asof.is/claim/clm_45941C7F343F","accessed":"2026-11-08"},"kind":"money","predicate":"research_and_development","value":"6,085,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_45941C7F343F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2020, filed 2021-02-17"}},{"date":"2020-12-31","until":"2021-03-31","published":"2021-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 5,641,600,000 United States dollar\", as of 2020-12-31 (until 2021-03-31). Claim clm_46B4CA545F87, https://asof.is/claim/clm_46B4CA545F87, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000083/0000059478-21-000083-index.htm.","url":"https://asof.is/claim/clm_46B4CA545F87","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"5,641,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_46B4CA545F87","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2020, filed 2021-02-17"}},{"date":"2020-12-31","until":"2021-12-31","published":"2021-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company net income: 6,193,700,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_AABFB7142885, https://asof.is/claim/clm_AABFB7142885, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000083/0000059478-21-000083-index.htm.","url":"https://asof.is/claim/clm_AABFB7142885","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"6,193,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AABFB7142885","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2020, filed 2021-02-17"}},{"date":"2020-12-31","until":"2021-03-31","published":"2021-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,657,100,000 United States dollar\", as of 2020-12-31 (until 2021-03-31). Claim clm_B1E745AC41C4, https://asof.is/claim/clm_B1E745AC41C4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000083/0000059478-21-000083-index.htm.","url":"https://asof.is/claim/clm_B1E745AC41C4","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,657,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B1E745AC41C4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2020, filed 2021-02-17"}},{"date":"2020-12-31","until":"2021-12-31","published":"2021-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company revenue: 24,539,800,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_E172D4945A79, https://asof.is/claim/clm_E172D4945A79, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000083/0000059478-21-000083-index.htm.","url":"https://asof.is/claim/clm_E172D4945A79","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"24,539,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E172D4945A79","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2020, filed 2021-02-17"}},{"date":"2020-12-31","until":"2021-03-31","published":"2021-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 46,633,100,000 United States dollar\", as of 2020-12-31 (until 2021-03-31). Claim clm_EB972D90100B, https://asof.is/claim/clm_EB972D90100B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000083/0000059478-21-000083-index.htm.","url":"https://asof.is/claim/clm_EB972D90100B","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"46,633,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EB972D90100B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2020, filed 2021-02-17"}},{"date":"2021-02-12","until":"2021-04-27","published":"2021-02-17","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 958,425,693 shares\", as of 2021-02-12 (until 2021-04-27). Claim clm_4F62576AFF4E, https://asof.is/claim/clm_4F62576AFF4E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000083/0000059478-21-000083-index.htm.","url":"https://asof.is/claim/clm_4F62576AFF4E","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"958,425,693 shares","status":"superseded","assertable":true,"id":"clm_4F62576AFF4E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2020, filed 2021-02-17"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,002,400,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_0E0B1A8912E6, https://asof.is/claim/clm_0E0B1A8912E6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000122/0000059478-21-000122-index.htm.","url":"https://asof.is/claim/clm_0E0B1A8912E6","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,002,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0E0B1A8912E6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2021, filed 2021-04-30"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 46,838,300,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_16B1DF07D73B, https://asof.is/claim/clm_16B1DF07D73B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000122/0000059478-21-000122-index.htm.","url":"https://asof.is/claim/clm_16B1DF07D73B","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"46,838,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_16B1DF07D73B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2021, filed 2021-04-30"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 6,805,600,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_97459A7EC040, https://asof.is/claim/clm_97459A7EC040, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000122/0000059478-21-000122-index.htm.","url":"https://asof.is/claim/clm_97459A7EC040","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"6,805,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_97459A7EC040","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2021, filed 2021-04-30"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,355,300,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_A256AB563F08, https://asof.is/claim/clm_A256AB563F08, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000122/0000059478-21-000122-index.htm.","url":"https://asof.is/claim/clm_A256AB563F08","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,355,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A256AB563F08","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2021, filed 2021-04-30"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,684,800,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_DB9BB042DAB8, https://asof.is/claim/clm_DB9BB042DAB8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000122/0000059478-21-000122-index.htm.","url":"https://asof.is/claim/clm_DB9BB042DAB8","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,684,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DB9BB042DAB8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2021, filed 2021-04-30"}},{"date":"2021-03-31","until":"2021-06-30","published":"2021-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 6,898,700,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_FDEFFA86C333, https://asof.is/claim/clm_FDEFFA86C333, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000122/0000059478-21-000122-index.htm.","url":"https://asof.is/claim/clm_FDEFFA86C333","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"6,898,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FDEFFA86C333","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2021, filed 2021-04-30"}},{"date":"2021-04-27","until":"2021-07-30","published":"2021-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 959,025,446 shares\", as of 2021-04-27 (until 2021-07-30). Claim clm_3086AC877E4A, https://asof.is/claim/clm_3086AC877E4A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000122/0000059478-21-000122-index.htm.","url":"https://asof.is/claim/clm_3086AC877E4A","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"959,025,446 shares","status":"superseded","assertable":true,"id":"clm_3086AC877E4A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2021, filed 2021-04-30"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,390,200,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_1BD4CEF67150, https://asof.is/claim/clm_1BD4CEF67150, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000171/0000059478-21-000171-index.htm.","url":"https://asof.is/claim/clm_1BD4CEF67150","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,390,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1BD4CEF67150","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2021, filed 2021-08-03"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,672,800,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_261A2B3FF924, https://asof.is/claim/clm_261A2B3FF924, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000171/0000059478-21-000171-index.htm.","url":"https://asof.is/claim/clm_261A2B3FF924","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,672,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_261A2B3FF924","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2021, filed 2021-08-03"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 47,809,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_47EC471C79DF, https://asof.is/claim/clm_47EC471C79DF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000171/0000059478-21-000171-index.htm.","url":"https://asof.is/claim/clm_47EC471C79DF","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"47,809,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_47EC471C79DF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2021, filed 2021-08-03"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 6,740,100,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_77D077A608D2, https://asof.is/claim/clm_77D077A608D2, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000171/0000059478-21-000171-index.htm.","url":"https://asof.is/claim/clm_77D077A608D2","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"6,740,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_77D077A608D2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2021, filed 2021-08-03"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,220,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_8C49EA5286AC, https://asof.is/claim/clm_8C49EA5286AC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000171/0000059478-21-000171-index.htm.","url":"https://asof.is/claim/clm_8C49EA5286AC","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,220,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8C49EA5286AC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2021, filed 2021-08-03"}},{"date":"2021-06-30","until":"2021-09-30","published":"2021-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 6,444,400,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_9D9F1AD72987, https://asof.is/claim/clm_9D9F1AD72987, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000171/0000059478-21-000171-index.htm.","url":"https://asof.is/claim/clm_9D9F1AD72987","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"6,444,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9D9F1AD72987","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2021, filed 2021-08-03"}},{"date":"2021-07-30","until":"2021-10-22","published":"2021-08-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 956,580,893 shares\", as of 2021-07-30 (until 2021-10-22). Claim clm_EA59F20B3B9B, https://asof.is/claim/clm_EA59F20B3B9B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000171/0000059478-21-000171-index.htm.","url":"https://asof.is/claim/clm_EA59F20B3B9B","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"956,580,893 shares","status":"superseded","assertable":true,"id":"clm_EA59F20B3B9B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2021, filed 2021-08-03"}},{"date":"2021-09-30","until":"2022-03-31","published":"2021-10-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,708,900,000 United States dollar\", as of 2021-09-30 (until 2022-03-31). Claim clm_0D1C949297F8, https://asof.is/claim/clm_0D1C949297F8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000216/0000059478-21-000216-index.htm.","url":"https://asof.is/claim/clm_0D1C949297F8","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,708,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0D1C949297F8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2021, filed 2021-10-27"}},{"date":"2021-09-30","until":"2021-12-31","published":"2021-10-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,788,200,000 United States dollar\", as of 2021-09-30 (until 2021-12-31). Claim clm_1FDCC26FC1A2, https://asof.is/claim/clm_1FDCC26FC1A2, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000216/0000059478-21-000216-index.htm.","url":"https://asof.is/claim/clm_1FDCC26FC1A2","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,788,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1FDCC26FC1A2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2021, filed 2021-10-27"}},{"date":"2021-09-30","until":"2022-03-31","published":"2021-10-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,110,100,000 United States dollar\", as of 2021-09-30 (until 2022-03-31). Claim clm_462A9B701577, https://asof.is/claim/clm_462A9B701577, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000216/0000059478-21-000216-index.htm.","url":"https://asof.is/claim/clm_462A9B701577","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,110,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_462A9B701577","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2021, filed 2021-10-27"}},{"date":"2021-09-30","until":"2021-12-31","published":"2021-10-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 7,757,000,000 United States dollar\", as of 2021-09-30 (until 2021-12-31). Claim clm_B6A71BBF205E, https://asof.is/claim/clm_B6A71BBF205E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000216/0000059478-21-000216-index.htm.","url":"https://asof.is/claim/clm_B6A71BBF205E","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"7,757,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B6A71BBF205E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2021, filed 2021-10-27"}},{"date":"2021-09-30","until":"2021-12-31","published":"2021-10-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 48,187,000,000 United States dollar\", as of 2021-09-30 (until 2021-12-31). Claim clm_D143A3FF1B0D, https://asof.is/claim/clm_D143A3FF1B0D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000216/0000059478-21-000216-index.htm.","url":"https://asof.is/claim/clm_D143A3FF1B0D","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"48,187,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D143A3FF1B0D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2021, filed 2021-10-27"}},{"date":"2021-09-30","until":"2022-03-31","published":"2021-10-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 6,772,800,000 United States dollar\", as of 2021-09-30 (until 2022-03-31). Claim clm_E26527683C4E, https://asof.is/claim/clm_E26527683C4E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000216/0000059478-21-000216-index.htm.","url":"https://asof.is/claim/clm_E26527683C4E","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"6,772,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E26527683C4E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2021, filed 2021-10-27"}},{"date":"2021-10-22","until":"2022-02-18","published":"2021-10-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 956,592,393 shares\", as of 2021-10-22 (until 2022-02-18). Claim clm_AD43BA302B07, https://asof.is/claim/clm_AD43BA302B07, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947821000216/0000059478-21-000216-index.htm.","url":"https://asof.is/claim/clm_AD43BA302B07","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"956,592,393 shares","status":"superseded","assertable":true,"id":"clm_AD43BA302B07","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2021, filed 2021-10-27"}},{"date":"2021-12-31","until":"2022-03-31","published":"2022-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,818,500,000 United States dollar\", as of 2021-12-31 (until 2022-03-31). Claim clm_1DE1F8B5A918, https://asof.is/claim/clm_1DE1F8B5A918, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000068/0000059478-22-000068-index.htm.","url":"https://asof.is/claim/clm_1DE1F8B5A918","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,818,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1DE1F8B5A918","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2021, filed 2022-02-23"}},{"date":"2021-12-31","until":"2022-03-31","published":"2022-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 48,806,000,000 United States dollar\", as of 2021-12-31 (until 2022-03-31). Claim clm_22AC4E6AFC98, https://asof.is/claim/clm_22AC4E6AFC98, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000068/0000059478-22-000068-index.htm.","url":"https://asof.is/claim/clm_22AC4E6AFC98","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"48,806,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_22AC4E6AFC98","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2021, filed 2022-02-23"}},{"date":"2021-12-31","until":"2022-12-31","published":"2022-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company revenue: 28,318,400,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_8786FF8AD12B, https://asof.is/claim/clm_8786FF8AD12B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000068/0000059478-22-000068-index.htm.","url":"https://asof.is/claim/clm_8786FF8AD12B","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"28,318,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8786FF8AD12B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2021, filed 2022-02-23"}},{"date":"2021-12-31","until":"2022-12-31","published":"2022-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company research and development: 7,025,900,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_92775F3E7CB5, https://asof.is/claim/clm_92775F3E7CB5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000068/0000059478-22-000068-index.htm.","url":"https://asof.is/claim/clm_92775F3E7CB5","accessed":"2026-11-08"},"kind":"money","predicate":"research_and_development","value":"7,025,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_92775F3E7CB5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2021, filed 2022-02-23"}},{"date":"2021-12-31","until":"2022-12-31","published":"2022-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company net income: 5,581,700,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_BE501ABAA6B4, https://asof.is/claim/clm_BE501ABAA6B4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000068/0000059478-22-000068-index.htm.","url":"https://asof.is/claim/clm_BE501ABAA6B4","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"5,581,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BE501ABAA6B4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2021, filed 2022-02-23"}},{"date":"2021-12-31","until":"2022-03-31","published":"2022-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 8,979,200,000 United States dollar\", as of 2021-12-31 (until 2022-03-31). Claim clm_E4583C178C44, https://asof.is/claim/clm_E4583C178C44, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000068/0000059478-22-000068-index.htm.","url":"https://asof.is/claim/clm_E4583C178C44","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"8,979,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E4583C178C44","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2021, filed 2022-02-23"}},{"date":"2022-02-18","until":"2022-04-26","published":"2022-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 952,347,126 shares\", as of 2022-02-18 (until 2022-04-26). Claim clm_D784DBD622DB, https://asof.is/claim/clm_D784DBD622DB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000068/0000059478-22-000068-index.htm.","url":"https://asof.is/claim/clm_D784DBD622DB","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"952,347,126 shares","status":"superseded","assertable":true,"id":"clm_D784DBD622DB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2021, filed 2022-02-23"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 9,330,800,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_0575AF1A3F2A, https://asof.is/claim/clm_0575AF1A3F2A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000133/0000059478-22-000133-index.htm.","url":"https://asof.is/claim/clm_0575AF1A3F2A","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"9,330,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0575AF1A3F2A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2022, filed 2022-04-29"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,902,900,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_082E003DAD72, https://asof.is/claim/clm_082E003DAD72, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000133/0000059478-22-000133-index.htm.","url":"https://asof.is/claim/clm_082E003DAD72","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,902,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_082E003DAD72","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2022, filed 2022-04-29"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 2,459,200,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_0A9E30C747EC, https://asof.is/claim/clm_0A9E30C747EC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000133/0000059478-22-000133-index.htm.","url":"https://asof.is/claim/clm_0A9E30C747EC","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,459,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0A9E30C747EC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2022, filed 2022-04-29"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,610,100,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_36AD989DA75C, https://asof.is/claim/clm_36AD989DA75C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000133/0000059478-22-000133-index.htm.","url":"https://asof.is/claim/clm_36AD989DA75C","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,610,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_36AD989DA75C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2022, filed 2022-04-29"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 46,919,300,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_5C9CBE97F7BA, https://asof.is/claim/clm_5C9CBE97F7BA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000133/0000059478-22-000133-index.htm.","url":"https://asof.is/claim/clm_5C9CBE97F7BA","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"46,919,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5C9CBE97F7BA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2022, filed 2022-04-29"}},{"date":"2022-03-31","until":"2022-06-30","published":"2022-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 7,810,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_DB3AB0C80149, https://asof.is/claim/clm_DB3AB0C80149, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000133/0000059478-22-000133-index.htm.","url":"https://asof.is/claim/clm_DB3AB0C80149","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"7,810,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DB3AB0C80149","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2022, filed 2022-04-29"}},{"date":"2022-04-26","until":"2022-08-01","published":"2022-04-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 950,159,559 shares\", as of 2022-04-26 (until 2022-08-01). Claim clm_D1A1C4F580B5, https://asof.is/claim/clm_D1A1C4F580B5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000133/0000059478-22-000133-index.htm.","url":"https://asof.is/claim/clm_D1A1C4F580B5","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"950,159,559 shares","status":"superseded","assertable":true,"id":"clm_D1A1C4F580B5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2022, filed 2022-04-29"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 6,488,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_5B96A4E73738, https://asof.is/claim/clm_5B96A4E73738, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000196/0000059478-22-000196-index.htm.","url":"https://asof.is/claim/clm_5B96A4E73738","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"6,488,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5B96A4E73738","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2022, filed 2022-08-04"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,781,900,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_7E87516D4A1A, https://asof.is/claim/clm_7E87516D4A1A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000196/0000059478-22-000196-index.htm.","url":"https://asof.is/claim/clm_7E87516D4A1A","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,781,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7E87516D4A1A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2022, filed 2022-08-04"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 2,622,900,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_922A5735F82B, https://asof.is/claim/clm_922A5735F82B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000196/0000059478-22-000196-index.htm.","url":"https://asof.is/claim/clm_922A5735F82B","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,622,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_922A5735F82B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2022, filed 2022-08-04"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 47,063,600,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_B64957C4E2C4, https://asof.is/claim/clm_B64957C4E2C4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000196/0000059478-22-000196-index.htm.","url":"https://asof.is/claim/clm_B64957C4E2C4","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"47,063,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B64957C4E2C4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2022, filed 2022-08-04"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 8,544,700,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_B8A59362EB8C, https://asof.is/claim/clm_B8A59362EB8C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000196/0000059478-22-000196-index.htm.","url":"https://asof.is/claim/clm_B8A59362EB8C","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"8,544,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B8A59362EB8C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2022, filed 2022-08-04"}},{"date":"2022-06-30","until":"2022-09-30","published":"2022-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 952,500,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_FC303DCB94C7, https://asof.is/claim/clm_FC303DCB94C7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000196/0000059478-22-000196-index.htm.","url":"https://asof.is/claim/clm_FC303DCB94C7","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"952,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FC303DCB94C7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2022, filed 2022-08-04"}},{"date":"2022-08-01","until":"2022-10-28","published":"2022-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 950,174,817 shares\", as of 2022-08-01 (until 2022-10-28). Claim clm_C28A879746A6, https://asof.is/claim/clm_C28A879746A6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000196/0000059478-22-000196-index.htm.","url":"https://asof.is/claim/clm_C28A879746A6","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"950,174,817 shares","status":"superseded","assertable":true,"id":"clm_C28A879746A6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2022, filed 2022-08-04"}},{"date":"2022-09-30","until":"2023-03-31","published":"2022-11-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,451,700,000 United States dollar\", as of 2022-09-30 (until 2023-03-31). Claim clm_2B253B0B594C, https://asof.is/claim/clm_2B253B0B594C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000250/0000059478-22-000250-index.htm.","url":"https://asof.is/claim/clm_2B253B0B594C","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,451,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2B253B0B594C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2022, filed 2022-11-01"}},{"date":"2022-09-30","until":"2022-12-31","published":"2022-11-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 10,070,100,000 United States dollar\", as of 2022-09-30 (until 2022-12-31). Claim clm_5FB739309DAD, https://asof.is/claim/clm_5FB739309DAD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000250/0000059478-22-000250-index.htm.","url":"https://asof.is/claim/clm_5FB739309DAD","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"10,070,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5FB739309DAD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2022, filed 2022-11-01"}},{"date":"2022-09-30","until":"2022-12-31","published":"2022-11-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 2,617,400,000 United States dollar\", as of 2022-09-30 (until 2022-12-31). Claim clm_AC838670E5D3, https://asof.is/claim/clm_AC838670E5D3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000250/0000059478-22-000250-index.htm.","url":"https://asof.is/claim/clm_AC838670E5D3","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,617,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AC838670E5D3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2022, filed 2022-11-01"}},{"date":"2022-09-30","until":"2022-12-31","published":"2022-11-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 47,461,500,000 United States dollar\", as of 2022-09-30 (until 2022-12-31). Claim clm_D68B1CE306FC, https://asof.is/claim/clm_D68B1CE306FC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000250/0000059478-22-000250-index.htm.","url":"https://asof.is/claim/clm_D68B1CE306FC","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"47,461,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D68B1CE306FC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2022, filed 2022-11-01"}},{"date":"2022-09-30","until":"2023-03-31","published":"2022-11-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,802,900,000 United States dollar\", as of 2022-09-30 (until 2023-03-31). Claim clm_DB412511FD99, https://asof.is/claim/clm_DB412511FD99, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000250/0000059478-22-000250-index.htm.","url":"https://asof.is/claim/clm_DB412511FD99","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,802,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DB412511FD99","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2022, filed 2022-11-01"}},{"date":"2022-09-30","until":"2023-03-31","published":"2022-11-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 6,941,600,000 United States dollar\", as of 2022-09-30 (until 2023-03-31). Claim clm_E29C4C5B9DDD, https://asof.is/claim/clm_E29C4C5B9DDD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000250/0000059478-22-000250-index.htm.","url":"https://asof.is/claim/clm_E29C4C5B9DDD","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"6,941,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E29C4C5B9DDD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2022, filed 2022-11-01"}},{"date":"2022-10-28","until":"2023-02-17","published":"2022-11-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 950,177,900 shares\", as of 2022-10-28 (until 2023-02-17). Claim clm_CEB639753736, https://asof.is/claim/clm_CEB639753736, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947822000250/0000059478-22-000250-index.htm.","url":"https://asof.is/claim/clm_CEB639753736","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"950,177,900 shares","status":"superseded","assertable":true,"id":"clm_CEB639753736","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2022, filed 2022-11-01"}},{"date":"2022-12-31","until":"2023-03-31","published":"2023-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 2,067,000,000 United States dollar\", as of 2022-12-31 (until 2023-03-31). Claim clm_17A0D356682C, https://asof.is/claim/clm_17A0D356682C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/0000059478-23-000082-index.htm.","url":"https://asof.is/claim/clm_17A0D356682C","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,067,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_17A0D356682C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2022, filed 2023-02-22"}},{"date":"2022-12-31","until":"2023-12-31","published":"2023-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company revenue: 28,541,400,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_4020D18C1AAA, https://asof.is/claim/clm_4020D18C1AAA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/0000059478-23-000082-index.htm.","url":"https://asof.is/claim/clm_4020D18C1AAA","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"28,541,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4020D18C1AAA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2022, filed 2023-02-22"}},{"date":"2022-12-31","until":null,"published":"2023-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company research and development: 7,190,800,000 United States dollar\", as of 2022-12-31. Claim clm_B291C97A9E9C, https://asof.is/claim/clm_B291C97A9E9C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/0000059478-23-000082-index.htm.","url":"https://asof.is/claim/clm_B291C97A9E9C","accessed":"2026-11-08"},"kind":"money","predicate":"research_and_development","value":"7,190,800,000 United States dollar","status":"valid","assertable":true,"id":"clm_B291C97A9E9C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2022, filed 2023-02-22"}},{"date":"2022-12-31","until":"2023-12-31","published":"2023-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company net income: 6,244,800,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_B3346D345CCB, https://asof.is/claim/clm_B3346D345CCB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/0000059478-23-000082-index.htm.","url":"https://asof.is/claim/clm_B3346D345CCB","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"6,244,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B3346D345CCB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2022, filed 2023-02-22"}},{"date":"2022-12-31","until":"2023-03-31","published":"2023-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 10,649,800,000 United States dollar\", as of 2022-12-31 (until 2023-03-31). Claim clm_F3CEC0454BF6, https://asof.is/claim/clm_F3CEC0454BF6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/0000059478-23-000082-index.htm.","url":"https://asof.is/claim/clm_F3CEC0454BF6","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"10,649,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F3CEC0454BF6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2022, filed 2023-02-22"}},{"date":"2022-12-31","until":"2023-03-31","published":"2023-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 49,489,800,000 United States dollar\", as of 2022-12-31 (until 2023-03-31). Claim clm_FB4B7491CC72, https://asof.is/claim/clm_FB4B7491CC72, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/0000059478-23-000082-index.htm.","url":"https://asof.is/claim/clm_FB4B7491CC72","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"49,489,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FB4B7491CC72","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2022, filed 2023-02-22"}},{"date":"2023-02-17","until":"2023-04-24","published":"2023-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 950,296,118 shares\", as of 2023-02-17 (until 2023-04-24). Claim clm_AFE76CCD74A1, https://asof.is/claim/clm_AFE76CCD74A1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000082/0000059478-23-000082-index.htm.","url":"https://asof.is/claim/clm_AFE76CCD74A1","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"950,296,118 shares","status":"superseded","assertable":true,"id":"clm_AFE76CCD74A1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2022, filed 2023-02-22"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 53,163,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_22782DC05585, https://asof.is/claim/clm_22782DC05585, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000162/0000059478-23-000162-index.htm.","url":"https://asof.is/claim/clm_22782DC05585","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"53,163,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_22782DC05585","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2023, filed 2023-04-27"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 1,985,100,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_28ED890F5BBC, https://asof.is/claim/clm_28ED890F5BBC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000162/0000059478-23-000162-index.htm.","url":"https://asof.is/claim/clm_28ED890F5BBC","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"1,985,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_28ED890F5BBC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2023, filed 2023-04-27"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,545,900,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_6E2BC5B4F6A4, https://asof.is/claim/clm_6E2BC5B4F6A4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000162/0000059478-23-000162-index.htm.","url":"https://asof.is/claim/clm_6E2BC5B4F6A4","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,545,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6E2BC5B4F6A4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2023, filed 2023-04-27"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 11,190,400,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_94BE166D8C14, https://asof.is/claim/clm_94BE166D8C14, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000162/0000059478-23-000162-index.htm.","url":"https://asof.is/claim/clm_94BE166D8C14","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"11,190,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_94BE166D8C14","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2023, filed 2023-04-27"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,344,900,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_9690B63B18DE, https://asof.is/claim/clm_9690B63B18DE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000162/0000059478-23-000162-index.htm.","url":"https://asof.is/claim/clm_9690B63B18DE","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,344,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9690B63B18DE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2023, filed 2023-04-27"}},{"date":"2023-03-31","until":"2023-06-30","published":"2023-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 6,960,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_CC9DB32026CE, https://asof.is/claim/clm_CC9DB32026CE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000162/0000059478-23-000162-index.htm.","url":"https://asof.is/claim/clm_CC9DB32026CE","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"6,960,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CC9DB32026CE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2023, filed 2023-04-27"}},{"date":"2023-04-24","until":"2023-08-03","published":"2023-04-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 949,272,933 shares\", as of 2023-04-24 (until 2023-08-03). Claim clm_31F67D187D33, https://asof.is/claim/clm_31F67D187D33, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000162/0000059478-23-000162-index.htm.","url":"https://asof.is/claim/clm_31F67D187D33","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"949,272,933 shares","status":"superseded","assertable":true,"id":"clm_31F67D187D33","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2023, filed 2023-04-27"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 11,063,800,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_1841AFF1FDCA, https://asof.is/claim/clm_1841AFF1FDCA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000221/0000059478-23-000221-index.htm.","url":"https://asof.is/claim/clm_1841AFF1FDCA","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"11,063,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1841AFF1FDCA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2023, filed 2023-08-08"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 2,694,500,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_296654FB728A, https://asof.is/claim/clm_296654FB728A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000221/0000059478-23-000221-index.htm.","url":"https://asof.is/claim/clm_296654FB728A","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,694,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_296654FB728A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2023, filed 2023-08-08"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 1,763,200,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_521AF355924A, https://asof.is/claim/clm_521AF355924A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000221/0000059478-23-000221-index.htm.","url":"https://asof.is/claim/clm_521AF355924A","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"1,763,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_521AF355924A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2023, filed 2023-08-08"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 54,814,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_71063E6D34A8, https://asof.is/claim/clm_71063E6D34A8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000221/0000059478-23-000221-index.htm.","url":"https://asof.is/claim/clm_71063E6D34A8","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"54,814,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_71063E6D34A8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2023, filed 2023-08-08"}},{"date":"2023-06-30","until":null,"published":"2023-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly research and development: 2,356,500,000 United States dollar\", as of 2023-06-30. Claim clm_A1B2A03455D9, https://asof.is/claim/clm_A1B2A03455D9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000221/0000059478-23-000221-index.htm.","url":"https://asof.is/claim/clm_A1B2A03455D9","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_research_and_development","value":"2,356,500,000 United States dollar","status":"valid","assertable":true,"id":"clm_A1B2A03455D9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2023, filed 2023-08-08"}},{"date":"2023-06-30","until":"2023-09-30","published":"2023-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 8,312,100,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_D152AA3878B8, https://asof.is/claim/clm_D152AA3878B8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000221/0000059478-23-000221-index.htm.","url":"https://asof.is/claim/clm_D152AA3878B8","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"8,312,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D152AA3878B8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2023, filed 2023-08-08"}},{"date":"2023-08-03","until":"2023-10-30","published":"2023-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 949,295,173 shares\", as of 2023-08-03 (until 2023-10-30). Claim clm_22F575B45357, https://asof.is/claim/clm_22F575B45357, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000221/0000059478-23-000221-index.htm.","url":"https://asof.is/claim/clm_22F575B45357","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"949,295,173 shares","status":"superseded","assertable":true,"id":"clm_22F575B45357","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2023, filed 2023-08-08"}},{"date":"2023-09-30","until":"2024-03-31","published":"2023-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 9,498,600,000 United States dollar\", as of 2023-09-30 (until 2024-03-31). Claim clm_3A1E7B4FAF72, https://asof.is/claim/clm_3A1E7B4FAF72, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000284/0000059478-23-000284-index.htm.","url":"https://asof.is/claim/clm_3A1E7B4FAF72","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"9,498,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3A1E7B4FAF72","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2023, filed 2023-11-02"}},{"date":"2023-09-30","until":"2023-12-31","published":"2023-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 11,220,400,000 United States dollar\", as of 2023-09-30 (until 2023-12-31). Claim clm_42DE1899560A, https://asof.is/claim/clm_42DE1899560A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000284/0000059478-23-000284-index.htm.","url":"https://asof.is/claim/clm_42DE1899560A","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"11,220,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_42DE1899560A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2023, filed 2023-11-02"}},{"date":"2023-09-30","until":"2023-12-31","published":"2023-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 2,380,800,000 United States dollar\", as of 2023-09-30 (until 2023-12-31). Claim clm_B4EB7A3B067D, https://asof.is/claim/clm_B4EB7A3B067D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000284/0000059478-23-000284-index.htm.","url":"https://asof.is/claim/clm_B4EB7A3B067D","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,380,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B4EB7A3B067D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2023, filed 2023-11-02"}},{"date":"2023-09-30","until":"2024-03-31","published":"2023-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: -57,400,000 United States dollar\", as of 2023-09-30 (until 2024-03-31). Claim clm_F0A26EC274C3, https://asof.is/claim/clm_F0A26EC274C3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000284/0000059478-23-000284-index.htm.","url":"https://asof.is/claim/clm_F0A26EC274C3","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"-57,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F0A26EC274C3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2023, filed 2023-11-02"}},{"date":"2023-09-30","until":"2023-12-31","published":"2023-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 57,915,500,000 United States dollar\", as of 2023-09-30 (until 2023-12-31). Claim clm_F973D4A69493, https://asof.is/claim/clm_F973D4A69493, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000284/0000059478-23-000284-index.htm.","url":"https://asof.is/claim/clm_F973D4A69493","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"57,915,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F973D4A69493","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2023, filed 2023-11-02"}},{"date":"2023-10-30","until":"2024-02-16","published":"2023-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 949,307,237 shares\", as of 2023-10-30 (until 2024-02-16). Claim clm_AC2092994972, https://asof.is/claim/clm_AC2092994972, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947823000284/0000059478-23-000284-index.htm.","url":"https://asof.is/claim/clm_AC2092994972","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"949,307,237 shares","status":"superseded","assertable":true,"id":"clm_AC2092994972","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2023, filed 2023-11-02"}},{"date":"2023-12-31","until":"2024-12-31","published":"2024-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company revenue: 34,124,100,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_2151D2F15ED6, https://asof.is/claim/clm_2151D2F15ED6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947824000065/0000059478-24-000065-index.htm.","url":"https://asof.is/claim/clm_2151D2F15ED6","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"34,124,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2151D2F15ED6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2023, filed 2024-02-21"}},{"date":"2023-12-31","until":"2024-03-31","published":"2024-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 10,771,900,000 United States dollar\", as of 2023-12-31 (until 2024-03-31). Claim clm_296E3EA8102E, https://asof.is/claim/clm_296E3EA8102E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947824000065/0000059478-24-000065-index.htm.","url":"https://asof.is/claim/clm_296E3EA8102E","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"10,771,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_296E3EA8102E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2023, filed 2024-02-21"}},{"date":"2023-12-31","until":"2024-12-31","published":"2024-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company net income: 5,240,400,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_2C28B4C8BA34, https://asof.is/claim/clm_2C28B4C8BA34, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947824000065/0000059478-24-000065-index.htm.","url":"https://asof.is/claim/clm_2C28B4C8BA34","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"5,240,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2C28B4C8BA34","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2023, filed 2024-02-21"}},{"date":"2023-12-31","until":"2024-03-31","published":"2024-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 64,006,300,000 United States dollar\", as of 2023-12-31 (until 2024-03-31). Claim clm_2E4C08058113, https://asof.is/claim/clm_2E4C08058113, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947824000065/0000059478-24-000065-index.htm.","url":"https://asof.is/claim/clm_2E4C08058113","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"64,006,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2E4C08058113","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2023, filed 2024-02-21"}},{"date":"2023-12-31","until":"2024-03-31","published":"2024-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 2,818,600,000 United States dollar\", as of 2023-12-31 (until 2024-03-31). Claim clm_C2EC357C8BE0, https://asof.is/claim/clm_C2EC357C8BE0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947824000065/0000059478-24-000065-index.htm.","url":"https://asof.is/claim/clm_C2EC357C8BE0","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,818,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C2EC357C8BE0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2023, filed 2024-02-21"}},{"date":"2024-02-16","until":"2024-04-25","published":"2024-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 950,164,452 shares\", as of 2024-02-16 (until 2024-04-25). Claim clm_C1C0A1DB1A21, https://asof.is/claim/clm_C1C0A1DB1A21, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947824000065/0000059478-24-000065-index.htm.","url":"https://asof.is/claim/clm_C1C0A1DB1A21","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"950,164,452 shares","status":"superseded","assertable":true,"id":"clm_C1C0A1DB1A21","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2023, filed 2024-02-21"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 63,943,500,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_1552D301A5B6, https://asof.is/claim/clm_1552D301A5B6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947824000118/0000059478-24-000118-index.htm.","url":"https://asof.is/claim/clm_1552D301A5B6","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"63,943,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1552D301A5B6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2024, filed 2024-04-30"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 8,768,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_1AD340C3A5DB, https://asof.is/claim/clm_1AD340C3A5DB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947824000118/0000059478-24-000118-index.htm.","url":"https://asof.is/claim/clm_1AD340C3A5DB","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"8,768,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1AD340C3A5DB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2024, filed 2024-04-30"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 2,460,200,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_20E22D66C75D, https://asof.is/claim/clm_20E22D66C75D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947824000118/0000059478-24-000118-index.htm.","url":"https://asof.is/claim/clm_20E22D66C75D","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"2,460,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_20E22D66C75D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2024, filed 2024-04-30"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 2,242,900,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_6D2F6DF42AAE, https://asof.is/claim/clm_6D2F6DF42AAE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947824000118/0000059478-24-000118-index.htm.","url":"https://asof.is/claim/clm_6D2F6DF42AAE","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"2,242,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6D2F6DF42AAE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2024, filed 2024-04-30"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 12,812,200,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_873AD40D49EA, https://asof.is/claim/clm_873AD40D49EA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947824000118/0000059478-24-000118-index.htm.","url":"https://asof.is/claim/clm_873AD40D49EA","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"12,812,200,000 United States dollar","status":"superseded","assertable":true,"id":"clm_873AD40D49EA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2024, filed 2024-04-30"}},{"date":"2024-04-25","until":"2024-08-05","published":"2024-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 950,405,386 shares\", as of 2024-04-25 (until 2024-08-05). Claim clm_A61E12A06FAE, https://asof.is/claim/clm_A61E12A06FAE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947824000118/0000059478-24-000118-index.htm.","url":"https://asof.is/claim/clm_A61E12A06FAE","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"950,405,386 shares","status":"superseded","assertable":true,"id":"clm_A61E12A06FAE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2024, filed 2024-04-30"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 11,302,800,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_3E94821DE7E1, https://asof.is/claim/clm_3E94821DE7E1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947824000187/0000059478-24-000187-index.htm.","url":"https://asof.is/claim/clm_3E94821DE7E1","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"11,302,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3E94821DE7E1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2024, filed 2024-08-08"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 2,967,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_50DC2A117A21, https://asof.is/claim/clm_50DC2A117A21, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947824000187/0000059478-24-000187-index.htm.","url":"https://asof.is/claim/clm_50DC2A117A21","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"2,967,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_50DC2A117A21","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2024, filed 2024-08-08"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 71,874,800,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_CD03F28D337B, https://asof.is/claim/clm_CD03F28D337B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947824000187/0000059478-24-000187-index.htm.","url":"https://asof.is/claim/clm_CD03F28D337B","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"71,874,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CD03F28D337B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2024, filed 2024-08-08"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,223,600,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_EB5CDAC12500, https://asof.is/claim/clm_EB5CDAC12500, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947824000187/0000059478-24-000187-index.htm.","url":"https://asof.is/claim/clm_EB5CDAC12500","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,223,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EB5CDAC12500","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2024, filed 2024-08-08"}},{"date":"2024-06-30","until":"2024-09-30","published":"2024-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 13,562,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_FE31C6766A8C, https://asof.is/claim/clm_FE31C6766A8C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947824000187/0000059478-24-000187-index.htm.","url":"https://asof.is/claim/clm_FE31C6766A8C","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"13,562,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FE31C6766A8C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2024, filed 2024-08-08"}},{"date":"2024-08-05","until":"2024-10-25","published":"2024-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 950,425,778 shares\", as of 2024-08-05 (until 2024-10-25). Claim clm_0C99C1CF2AF4, https://asof.is/claim/clm_0C99C1CF2AF4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947824000187/0000059478-24-000187-index.htm.","url":"https://asof.is/claim/clm_0C99C1CF2AF4","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"950,425,778 shares","status":"superseded","assertable":true,"id":"clm_0C99C1CF2AF4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2024, filed 2024-08-08"}},{"date":"2024-09-30","until":"2025-03-31","published":"2024-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 11,439,100,000 United States dollar\", as of 2024-09-30 (until 2025-03-31). Claim clm_0D9BE0B6BA02, https://asof.is/claim/clm_0D9BE0B6BA02, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947824000245/0000059478-24-000245-index.htm.","url":"https://asof.is/claim/clm_0D9BE0B6BA02","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"11,439,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0D9BE0B6BA02","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2024, filed 2024-10-30"}},{"date":"2024-09-30","until":"2025-03-31","published":"2024-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 970,300,000 United States dollar\", as of 2024-09-30 (until 2025-03-31). Claim clm_49D1BFE1C6AA, https://asof.is/claim/clm_49D1BFE1C6AA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947824000245/0000059478-24-000245-index.htm.","url":"https://asof.is/claim/clm_49D1BFE1C6AA","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"970,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_49D1BFE1C6AA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2024, filed 2024-10-30"}},{"date":"2024-09-30","until":"2024-12-31","published":"2024-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 75,606,900,000 United States dollar\", as of 2024-09-30 (until 2024-12-31). Claim clm_52866FB31BA7, https://asof.is/claim/clm_52866FB31BA7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947824000245/0000059478-24-000245-index.htm.","url":"https://asof.is/claim/clm_52866FB31BA7","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"75,606,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_52866FB31BA7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2024, filed 2024-10-30"}},{"date":"2024-09-30","until":"2024-12-31","published":"2024-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 14,240,000,000 United States dollar\", as of 2024-09-30 (until 2024-12-31). Claim clm_F543E95F6B84, https://asof.is/claim/clm_F543E95F6B84, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947824000245/0000059478-24-000245-index.htm.","url":"https://asof.is/claim/clm_F543E95F6B84","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"14,240,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F543E95F6B84","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2024, filed 2024-10-30"}},{"date":"2024-09-30","until":"2024-12-31","published":"2024-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,369,000,000 United States dollar\", as of 2024-09-30 (until 2024-12-31). Claim clm_F6EB021B631B, https://asof.is/claim/clm_F6EB021B631B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947824000245/0000059478-24-000245-index.htm.","url":"https://asof.is/claim/clm_F6EB021B631B","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,369,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F6EB021B631B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2024, filed 2024-10-30"}},{"date":"2024-10-25","until":"2025-02-14","published":"2024-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 949,315,694 shares\", as of 2024-10-25 (until 2025-02-14). Claim clm_2F9C4C1E5AC6, https://asof.is/claim/clm_2F9C4C1E5AC6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947824000245/0000059478-24-000245-index.htm.","url":"https://asof.is/claim/clm_2F9C4C1E5AC6","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"949,315,694 shares","status":"superseded","assertable":true,"id":"clm_2F9C4C1E5AC6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2024, filed 2024-10-30"}},{"date":"2024-12-31","until":"2025-12-31","published":"2025-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company revenue: 45,042,700,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_282E1F71B318, https://asof.is/claim/clm_282E1F71B318, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000067/0000059478-25-000067-index.htm.","url":"https://asof.is/claim/clm_282E1F71B318","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"45,042,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_282E1F71B318","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2024, filed 2025-02-19"}},{"date":"2024-12-31","until":"2025-12-31","published":"2025-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company net income: 10,590,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_2BC21A73296C, https://asof.is/claim/clm_2BC21A73296C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000067/0000059478-25-000067-index.htm.","url":"https://asof.is/claim/clm_2BC21A73296C","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"10,590,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2BC21A73296C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-19"}},{"date":"2024-12-31","until":"2025-03-31","published":"2025-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 14,192,100,000 United States dollar\", as of 2024-12-31 (until 2025-03-31). Claim clm_3C3D7729DB02, https://asof.is/claim/clm_3C3D7729DB02, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000067/0000059478-25-000067-index.htm.","url":"https://asof.is/claim/clm_3C3D7729DB02","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"14,192,100,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3C3D7729DB02","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2024, filed 2025-02-19"}},{"date":"2024-12-31","until":"2025-03-31","published":"2025-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 78,714,900,000 United States dollar\", as of 2024-12-31 (until 2025-03-31). Claim clm_4B929E4D8044, https://asof.is/claim/clm_4B929E4D8044, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000067/0000059478-25-000067-index.htm.","url":"https://asof.is/claim/clm_4B929E4D8044","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"78,714,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4B929E4D8044","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2024, filed 2025-02-19"}},{"date":"2024-12-31","until":"2025-03-31","published":"2025-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,268,400,000 United States dollar\", as of 2024-12-31 (until 2025-03-31). Claim clm_DBC8478F7F2C, https://asof.is/claim/clm_DBC8478F7F2C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000067/0000059478-25-000067-index.htm.","url":"https://asof.is/claim/clm_DBC8478F7F2C","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,268,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DBC8478F7F2C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2024, filed 2025-02-19"}},{"date":"2025-02-14","until":"2025-04-28","published":"2025-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 948,169,999 shares\", as of 2025-02-14 (until 2025-04-28). Claim clm_85B1F2DD64D4, https://asof.is/claim/clm_85B1F2DD64D4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000067/0000059478-25-000067-index.htm.","url":"https://asof.is/claim/clm_85B1F2DD64D4","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"948,169,999 shares","status":"superseded","assertable":true,"id":"clm_85B1F2DD64D4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2024, filed 2025-02-19"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 12,728,500,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_684F3B3B6CFA, https://asof.is/claim/clm_684F3B3B6CFA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000132/0000059478-25-000132-index.htm.","url":"https://asof.is/claim/clm_684F3B3B6CFA","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"12,728,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_684F3B3B6CFA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2025, filed 2025-05-01"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 2,759,300,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_ABF5DA9F3F8E, https://asof.is/claim/clm_ABF5DA9F3F8E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000132/0000059478-25-000132-index.htm.","url":"https://asof.is/claim/clm_ABF5DA9F3F8E","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"2,759,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_ABF5DA9F3F8E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2025, filed 2025-05-01"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 15,764,800,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_BAC94969E9C8, https://asof.is/claim/clm_BAC94969E9C8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000132/0000059478-25-000132-index.htm.","url":"https://asof.is/claim/clm_BAC94969E9C8","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"15,764,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BAC94969E9C8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2025, filed 2025-05-01"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,093,300,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_F076409F4247, https://asof.is/claim/clm_F076409F4247, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000132/0000059478-25-000132-index.htm.","url":"https://asof.is/claim/clm_F076409F4247","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,093,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F076409F4247","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2025, filed 2025-05-01"}},{"date":"2025-03-31","until":"2025-06-30","published":"2025-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 89,388,800,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_FFD575F8F24D, https://asof.is/claim/clm_FFD575F8F24D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000132/0000059478-25-000132-index.htm.","url":"https://asof.is/claim/clm_FFD575F8F24D","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"89,388,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FFD575F8F24D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2025, filed 2025-05-01"}},{"date":"2025-04-28","until":"2025-08-04","published":"2025-05-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 947,735,651 shares\", as of 2025-04-28 (until 2025-08-04). Claim clm_AA7B6785A235, https://asof.is/claim/clm_AA7B6785A235, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000132/0000059478-25-000132-index.htm.","url":"https://asof.is/claim/clm_AA7B6785A235","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"947,735,651 shares","status":"superseded","assertable":true,"id":"clm_AA7B6785A235","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2025, filed 2025-05-01"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 5,660,500,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_1D33827F581C, https://asof.is/claim/clm_1D33827F581C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000204/0000059478-25-000204-index.htm.","url":"https://asof.is/claim/clm_1D33827F581C","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"5,660,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1D33827F581C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2025, filed 2025-08-07"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 100,922,600,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_448FFB239F79, https://asof.is/claim/clm_448FFB239F79, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000204/0000059478-25-000204-index.htm.","url":"https://asof.is/claim/clm_448FFB239F79","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"100,922,600,000 United States dollar","status":"superseded","assertable":true,"id":"clm_448FFB239F79","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2025, filed 2025-08-07"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 3,375,900,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_6393A6D7AE8B, https://asof.is/claim/clm_6393A6D7AE8B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000204/0000059478-25-000204-index.htm.","url":"https://asof.is/claim/clm_6393A6D7AE8B","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"3,375,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6393A6D7AE8B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2025, filed 2025-08-07"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 15,557,700,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_7CBD9D7BE5AE, https://asof.is/claim/clm_7CBD9D7BE5AE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000204/0000059478-25-000204-index.htm.","url":"https://asof.is/claim/clm_7CBD9D7BE5AE","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"15,557,700,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7CBD9D7BE5AE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2025, filed 2025-08-07"}},{"date":"2025-06-30","until":"2025-09-30","published":"2025-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 18,272,900,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_8BC2286999EC, https://asof.is/claim/clm_8BC2286999EC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000204/0000059478-25-000204-index.htm.","url":"https://asof.is/claim/clm_8BC2286999EC","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"18,272,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8BC2286999EC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2025, filed 2025-08-07"}},{"date":"2025-08-04","until":"2025-10-27","published":"2025-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 946,456,759 shares\", as of 2025-08-04 (until 2025-10-27). Claim clm_038B0512B15D, https://asof.is/claim/clm_038B0512B15D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000204/0000059478-25-000204-index.htm.","url":"https://asof.is/claim/clm_038B0512B15D","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"946,456,759 shares","status":"superseded","assertable":true,"id":"clm_038B0512B15D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2025, filed 2025-08-07"}},{"date":"2025-09-30","until":"2025-12-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 9,791,900,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_599C7D287C29, https://asof.is/claim/clm_599C7D287C29, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm.","url":"https://asof.is/claim/clm_599C7D287C29","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"9,791,900,000 United States dollar","status":"superseded","assertable":true,"id":"clm_599C7D287C29","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2025, filed 2025-10-30"}},{"date":"2025-09-30","until":"2026-03-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 5,582,500,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_74B5C29B477B, https://asof.is/claim/clm_74B5C29B477B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm.","url":"https://asof.is/claim/clm_74B5C29B477B","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"5,582,500,000 United States dollar","status":"superseded","assertable":true,"id":"clm_74B5C29B477B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-10-30"}},{"date":"2025-09-30","until":"2025-12-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 23,793,300,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_AA3E6D040F0E, https://asof.is/claim/clm_AA3E6D040F0E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm.","url":"https://asof.is/claim/clm_AA3E6D040F0E","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"23,793,300,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AA3E6D040F0E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-10-30"}},{"date":"2025-09-30","until":"2025-12-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 114,935,400,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_C3E87E59336F, https://asof.is/claim/clm_C3E87E59336F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm.","url":"https://asof.is/claim/clm_C3E87E59336F","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"114,935,400,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C3E87E59336F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-10-30"}},{"date":"2025-09-30","until":"2026-03-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 17,600,800,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_D3881089FBD6, https://asof.is/claim/clm_D3881089FBD6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm.","url":"https://asof.is/claim/clm_D3881089FBD6","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"17,600,800,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D3881089FBD6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2025, filed 2025-10-30"}},{"date":"2025-10-27","until":"2026-02-09","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 945,383,757 shares\", as of 2025-10-27 (until 2026-02-09). Claim clm_3242C5557E98, https://asof.is/claim/clm_3242C5557E98, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm.","url":"https://asof.is/claim/clm_3242C5557E98","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"945,383,757 shares","status":"superseded","assertable":true,"id":"clm_3242C5557E98","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2025, filed 2025-10-30"}},{"date":"2025-12-31","until":"2026-03-31","published":"2026-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 26,535,000,000 United States dollar\", as of 2025-12-31 (until 2026-03-31). Claim clm_6628DA8282A8, https://asof.is/claim/clm_6628DA8282A8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/0000059478-26-000013-index.htm.","url":"https://asof.is/claim/clm_6628DA8282A8","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"26,535,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6628DA8282A8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2025, filed 2026-02-12"}},{"date":"2025-12-31","until":"2026-03-31","published":"2026-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 7,268,000,000 United States dollar\", as of 2025-12-31 (until 2026-03-31). Claim clm_AEB07A485FC9, https://asof.is/claim/clm_AEB07A485FC9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/0000059478-26-000013-index.htm.","url":"https://asof.is/claim/clm_AEB07A485FC9","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"7,268,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AEB07A485FC9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2025, filed 2026-02-12"}},{"date":"2025-12-31","until":"2026-03-31","published":"2026-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 112,476,000,000 United States dollar\", as of 2025-12-31 (until 2026-03-31). Claim clm_C278ED944402, https://asof.is/claim/clm_C278ED944402, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/0000059478-26-000013-index.htm.","url":"https://asof.is/claim/clm_C278ED944402","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"112,476,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C278ED944402","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2025, filed 2026-02-12"}},{"date":"2025-12-31","until":null,"published":"2026-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company revenue: 65,179,000,000 United States dollar\", as of 2025-12-31. Claim clm_C4636B99C62B, https://asof.is/claim/clm_C4636B99C62B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/0000059478-26-000013-index.htm.","url":"https://asof.is/claim/clm_C4636B99C62B","accessed":"2026-11-08"},"kind":"money","predicate":"revenue","value":"65,179,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_C4636B99C62B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2025, filed 2026-02-12"}},{"date":"2025-12-31","until":null,"published":"2026-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company net income: 20,640,000,000 United States dollar\", as of 2025-12-31. Claim clm_DBEC55E24C06, https://asof.is/claim/clm_DBEC55E24C06, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/0000059478-26-000013-index.htm.","url":"https://asof.is/claim/clm_DBEC55E24C06","accessed":"2026-11-08"},"kind":"money","predicate":"net_income","value":"20,640,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_DBEC55E24C06","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2025, filed 2026-02-12"}},{"date":"2026-02-09","until":"2026-04-27","published":"2026-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 943,357,420 shares\", as of 2026-02-09 (until 2026-04-27). Claim clm_5A4FA78D8054, https://asof.is/claim/clm_5A4FA78D8054, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/0000059478-26-000013-index.htm.","url":"https://asof.is/claim/clm_5A4FA78D8054","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"943,357,420 shares","status":"superseded","assertable":true,"id":"clm_5A4FA78D8054","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2025, filed 2026-02-12"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 7,396,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_063460475B4C, https://asof.is/claim/clm_063460475B4C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000045/0000059478-26-000045-index.htm.","url":"https://asof.is/claim/clm_063460475B4C","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"7,396,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_063460475B4C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2026, filed 2026-04-30"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 31,198,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_288F177A8B4B, https://asof.is/claim/clm_288F177A8B4B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000045/0000059478-26-000045-index.htm.","url":"https://asof.is/claim/clm_288F177A8B4B","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"31,198,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_288F177A8B4B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2026, filed 2026-04-30"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 5,282,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_413E49925EF9, https://asof.is/claim/clm_413E49925EF9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000045/0000059478-26-000045-index.htm.","url":"https://asof.is/claim/clm_413E49925EF9","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"5,282,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_413E49925EF9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2026, filed 2026-04-30"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 116,576,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_A36CAC6CDD99, https://asof.is/claim/clm_A36CAC6CDD99, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000045/0000059478-26-000045-index.htm.","url":"https://asof.is/claim/clm_A36CAC6CDD99","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"116,576,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A36CAC6CDD99","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2026, filed 2026-04-30"}},{"date":"2026-03-31","until":"2026-06-30","published":"2026-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 19,799,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_DF742A5515B7, https://asof.is/claim/clm_DF742A5515B7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000045/0000059478-26-000045-index.htm.","url":"https://asof.is/claim/clm_DF742A5515B7","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"19,799,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DF742A5515B7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2026, filed 2026-04-30"}},{"date":"2026-04-27","until":"2026-08-03","published":"2026-04-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 941,741,406 shares\", as of 2026-04-27 (until 2026-08-03). Claim clm_1DF27D28FE37, https://asof.is/claim/clm_1DF27D28FE37, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000045/0000059478-26-000045-index.htm.","url":"https://asof.is/claim/clm_1DF27D28FE37","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"941,741,406 shares","status":"superseded","assertable":true,"id":"clm_1DF27D28FE37","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2026, filed 2026-04-30"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 142,283,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_2F9AF66FD3E4, https://asof.is/claim/clm_2F9AF66FD3E4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/0000059478-26-000081-index.htm.","url":"https://asof.is/claim/clm_2F9AF66FD3E4","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"142,283,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2F9AF66FD3E4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2026, filed 2026-08-05"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 7,095,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_2FBA71C4F385, https://asof.is/claim/clm_2FBA71C4F385, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/0000059478-26-000081-index.htm.","url":"https://asof.is/claim/clm_2FBA71C4F385","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"7,095,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2FBA71C4F385","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2026, filed 2026-08-05"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 8,950,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_B021E511C567, https://asof.is/claim/clm_B021E511C567, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/0000059478-26-000081-index.htm.","url":"https://asof.is/claim/clm_B021E511C567","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"8,950,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B021E511C567","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2026, filed 2026-08-05"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 33,879,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_B27C7F5364BF, https://asof.is/claim/clm_B27C7F5364BF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/0000059478-26-000081-index.htm.","url":"https://asof.is/claim/clm_B27C7F5364BF","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"33,879,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B27C7F5364BF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2026, filed 2026-08-05"}},{"date":"2026-06-30","until":"2026-09-30","published":"2026-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 22,974,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_D2C1E8A7329C, https://asof.is/claim/clm_D2C1E8A7329C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/0000059478-26-000081-index.htm.","url":"https://asof.is/claim/clm_D2C1E8A7329C","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"22,974,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D2C1E8A7329C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2026, filed 2026-08-05"}},{"date":"2026-08-03","until":"2026-10-26","published":"2026-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 941,357,065 shares\", as of 2026-08-03 (until 2026-10-26). Claim clm_0BBEC8AC9C68, https://asof.is/claim/clm_0BBEC8AC9C68, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/0000059478-26-000081-index.htm.","url":"https://asof.is/claim/clm_0BBEC8AC9C68","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"941,357,065 shares","status":"superseded","assertable":true,"id":"clm_0BBEC8AC9C68","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2026, filed 2026-08-05"}},{"date":"2026-09-30","until":null,"published":"2026-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 40,271,000,000 United States dollar\", as of 2026-09-30. Claim clm_82ACC132512E, https://asof.is/claim/clm_82ACC132512E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm.","url":"https://asof.is/claim/clm_82ACC132512E","accessed":"2026-11-08"},"kind":"money","predicate":"total_equity","value":"40,271,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_82ACC132512E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2026, filed 2026-10-29"}},{"date":"2026-09-30","until":null,"published":"2026-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 6,451,000,000 United States dollar\", as of 2026-09-30. Claim clm_9D57FD94603E, https://asof.is/claim/clm_9D57FD94603E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm.","url":"https://asof.is/claim/clm_9D57FD94603E","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_net_income","value":"6,451,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_9D57FD94603E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2026, filed 2026-10-29"}},{"date":"2026-09-30","until":null,"published":"2026-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 4,885,000,000 United States dollar\", as of 2026-09-30. Claim clm_BC1171A7B218, https://asof.is/claim/clm_BC1171A7B218, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm.","url":"https://asof.is/claim/clm_BC1171A7B218","accessed":"2026-11-08"},"kind":"money","predicate":"cash_and_equivalents","value":"4,885,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_BC1171A7B218","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2026, filed 2026-10-29"}},{"date":"2026-09-30","until":null,"published":"2026-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 148,072,000,000 United States dollar\", as of 2026-09-30. Claim clm_D20ADDDE60AB, https://asof.is/claim/clm_D20ADDDE60AB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm.","url":"https://asof.is/claim/clm_D20ADDDE60AB","accessed":"2026-11-08"},"kind":"money","predicate":"total_assets","value":"148,072,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_D20ADDDE60AB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2026, filed 2026-10-29"}},{"date":"2026-09-30","until":null,"published":"2026-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 24,397,000,000 United States dollar\", as of 2026-09-30. Claim clm_E1B01E0405B5, https://asof.is/claim/clm_E1B01E0405B5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm.","url":"https://asof.is/claim/clm_E1B01E0405B5","accessed":"2026-11-08"},"kind":"money","predicate":"quarterly_revenue","value":"24,397,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_E1B01E0405B5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2026, filed 2026-10-29"}},{"date":"2026-10-26","until":null,"published":"2026-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 940,745,031 shares\", as of 2026-10-26. Claim clm_ACF69B8AA825, https://asof.is/claim/clm_ACF69B8AA825, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm.","url":"https://asof.is/claim/clm_ACF69B8AA825","accessed":"2026-11-08"},"kind":"money","predicate":"shares_outstanding","value":"940,745,031 shares","status":"valid","assertable":true,"id":"clm_ACF69B8AA825","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2026, filed 2026-10-29"}}],"complete":true,"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing"}}}